George Karvelas, Denis Lebel and Lionel Carmant978-1-59259-808-3/1.pdf · George Karvelas, Denis...
43
Appendix A The Carbohydrate and Caloric Content of Drugs George Karvelas, Denis Lebel and Lionel Carmant As mentioned in several chapters of this volume, complete or even partial loss of ketosis can lead to acute seizure recurrence and can even impair long-term seizure con- trol ( 1 ). Although the exact mechanism of action of the ketogenic diet (KD) remains uncertain, maintenance of ketosis is mandatory for improved seizure control (2). For these reasons, and because the amount of carbohydrates and proteins is strictly limited in the KD, strict compliance to the diet is of foremost importance. In children, the control of caloric intake can be difficult owing to the availability of carbohydrates and calories from different sources. The optimal management of the ketogenic diet requires the collaboration of siblings, school personnel, classmates, and nursing and hospital staff. During the 2 yr or more of the diet, modifications in the use of chronic medications and acute treatment for intercurrent illnesses must also be taken into account. Syrups are usually contraindicated because of their high carbo- hydrate content in the form of sucrose, maltose, sorbitol, mannitol, alcohol, or starch. A number of caregivers are however unaware that the "sugar-free" label of drug tablets does not guarantee that ketosis will not be affected. These drugs may contain sorbitol, a carbohydrate that does not affect glycemia but will alter ketosis. The knowledge of the carbohydrate and caloric content of these drugs will help physi- cians, dieticians, and nurses adjust the diet .accordingly. We therefore developed a comprehensive table of all commonly used drugs for which the information was available (Table 1) (3). For some medications, the data are not readily available. We therefore developed a worst-case scenario that in our experience always overestimates the caloric content of these medications (Table 2). To obtain this estimation, one needs to measure the weight of 10 tablets of a given drug, subtract the amount of active material in these tablets, and then divide the result by the number of tablets weighed. We consider this number to represent the maximal carbohydrate content of the pharmaceutical formulation in grams. Extrapolating the energy content by multiplying the calculated number by 4 kcal as the worst-case scenario assumes that all this weight comprises carbohydrates. From: Epilepsy and the Ketogenic Diet Edited by: C. E. Stafstrom and J. M. Rho © Humana Press Inc., Totowa, NJ 311
Transcript of George Karvelas, Denis Lebel and Lionel Carmant978-1-59259-808-3/1.pdf · George Karvelas, Denis...
Appendix A The Carbohydrate and Caloric Content of Drugs
George Karvelas, Denis Lebel and Lionel Carmant
As mentioned in several chapters of this volume, complete or even partial loss of ketosis can lead to acute seizure recurrence and can even impair long-term seizure control ( 1 ). Although the exact mechanism of action of the ketogenic diet (KD) remains uncertain, maintenance of ketosis is mandatory for improved seizure control (2). For these reasons, and because the amount of carbohydrates and proteins is strictly limited in the KD, strict compliance to the diet is of foremost importance.
In children, the control of caloric intake can be difficult owing to the availability of carbohydrates and calories from different sources. The optimal management of the ketogenic diet requires the collaboration of siblings, school personnel, classmates, and nursing and hospital staff. During the 2 yr or more of the diet, modifications in the use of chronic medications and acute treatment for intercurrent illnesses must also be taken into account. Syrups are usually contraindicated because of their high carbohydrate content in the form of sucrose, maltose, sorbitol, mannitol, alcohol, or starch. A number of caregivers are however unaware that the "sugar-free" label of drug tablets does not guarantee that ketosis will not be affected. These drugs may contain sorbitol, a carbohydrate that does not affect glycemia but will alter ketosis. The knowledge of the carbohydrate and caloric content of these drugs will help physicians, dieticians, and nurses adjust the diet .accordingly. We therefore developed a comprehensive table of all commonly used drugs for which the information was available (Table 1) (3).
For some medications, the data are not readily available. We therefore developed a worst-case scenario that in our experience always overestimates the caloric content of these medications (Table 2). To obtain this estimation, one needs to measure the weight of 10 tablets of a given drug, subtract the amount of active material in these tablets, and then divide the result by the number of tablets weighed. We consider this number to represent the maximal carbohydrate content of the pharmaceutical formulation in grams. Extrapolating the energy content by multiplying the calculated number by 4 kcal as the worst -case scenario assumes that all this weight comprises carbohydrates.
From: Epilepsy and the Ketogenic Diet Edited by: C. E. Stafstrom and J. M. Rho © Humana Press Inc., Totowa, NJ
311
Tab
le 1
C
alor
ic C
onte
nt o
f Dru
gs,
Lis
ted
by G
ener
ic N
ames
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n C
omm
erci
al n
ame
and
com
pany
C
arbo
hydr
ateb
To
ta[b
5-A
min
osal
icyl
ic a
cid,
250
mgf
fabl
et
Pen
tasa
(H
oech
st M
ario
n R
ouss
el)
0.00
N
d 5-
Am
inos
alic
ylic
aci
d, 5
00 m
gffa
blet
P
enta
sa (
Hoe
chst
Mar
ion
Rou
ssel
) 0.
00
Nd
Ace
buto
lol
HC
l, 1
00 m
gffa
blet
N
ovo-
Ace
buto
l (N
ovop
harm
) 0.
360
0.37
5 A
cebu
tolo
l H
Cl,
200
mgf
fabl
et
Nov
o-A
cebu
tol
(Nov
opha
rm)
0.72
0 0.
749
Ace
buto
lol
HC
l, 4
00 m
gffa
blet
N
ovo-
Ace
buto
l (N
ovop
harm
) 0.
025
0.06
6 A
ceta
min
ophe
n, 1
6 m
g/m
L/L
iqui
d T
empr
a (M
ead
John
son)
N
d 1.
78
Ace
tam
inop
hen,
16
mg/
mL
!Liq
uid
Ata
sol
(Car
ter
Hor
ner)
1.
44
2.40
A
ceta
min
ophe
n, 1
6 m
g/m
L!L
iqui
d P
MS
-ace
tam
inop
hen
(Pha
rmas
cien
ce)
1.7
Nd
Ace
tam
inop
hen,
160
mg/
Che
wab
le ta
blet
T
ylen
ol (
McN
eil)
N
d 2.
5 \.)
;1
Ace
tam
inop
hen,
160
mg/
Che
wab
le t
able
t T
ylen
ol,
suga
r fr
ee (
McN
eil)
N
d 2.
0 - A
ceta
min
ophe
n, 3
2 m
g/m
L/L
iqui
d T
empr
a (M
ead
John
son)
N
d 1.
78
N
Ace
tam
inop
hen,
32
mg/
mL
/Liq
uid
Tyl
enol
eli
xir
(McN
eil)
N
d 1.
76
Ace
tam
inop
hen,
32
mg/
mL
!Liq
uid
Tyl
enol
sus
pens
ion
liqu
id (
rais
in)
(McN
eil)
N
d 2.
22
Ace
tam
inop
hen,
32
mg/
mL
!Liq
uid
Tyl
enol
sus
pens
ion
liqu
id (
bubb
legu
m)
(McN
eil)
N
d 2.
40
Ace
tam
inop
hen,
32
mg/
mL
/Liq
uid
PM
S-a
ceta
min
ophe
n (P
harm
asci
ence
) 1.
7 N
d A
ceta
min
ophe
n, 3
25 m
gffa
blet
T
ylen
ol (
McN
eil)
N
d 0.
2 A
ceta
min
ophe
n, 3
25 m
gffa
blet
N
ovo-
Ges
ic (
Nov
opha
rm)
0.03
9 N
d A
ceta
min
ophe
n, 5
00 m
gffa
blet
T
ylen
ol (
McN
eil)
N
d 0.
3 A
ceta
min
ophe
n, 5
00 m
gffa
blet
N
ovo-
Ges
ic (
Nov
opha
rm)
0.06
2 N
d A
ceta
min
ophe
n, 8
0 m
g/C
hew
able
tab
let
Tyl
enol
(M
cNei
l)
Nd
1.2
Ace
tam
inop
hen,
80
mg/
Che
wab
le ta
blet
T
ylen
ol,
suga
r fr
ee (
McN
eil)
N
d 1
Ace
tam
inop
hen,
80
mg/
mL
/Liq
uid
Tem
pra
(Mea
d Jo
hnso
n)
Nd
1.40
A
ceta
min
ophe
n, 8
0 m
g/m
L!L
iqui
d T
ylen
ol d
rops
(M
cNei
l)
Nd
0.98
A
ceta
min
ophe
n, 8
0 m
g/m
L!L
iqui
d T
ylen
ol s
uspe
nsio
ns, d
rops
(M
cNei
l)
Nd
2.10
A
ceta
min
ophe
n, 8
0 m
g/m
L/L
iqui
d P
MS
-Ace
tam
inop
hen
(Pha
rmas
cien
ce)
0.36
N
d
Ace
tam
inop
hen,
80
mg/
ml!
Liq
uid
Ata
sol
drop
s (C
arte
r H
omer
) 1.
79
2.40
A
ceta
min
ophe
n-ca
ffei
ne-c
odei
ne p
hosp
hate
(C
15),
N
ovo-
Ges
ic C
IS (
Nov
opha
rm)
0.14
8 0.
188
300
mg
+ 1
5 m
g +
15
mgf
fabl
et
Ace
tam
inop
hen-
caff
eine
-cod
eine
pho
spha
te (
C30
),
Nov
o-G
esic
C30
(N
ovop
harm
) 0.
154
0.19
5 30
0 m
g +
15
mg
+ 3
0 m
gffa
blet
A
ceta
min
ophe
n-ca
ffei
ne-c
odei
ne p
hosp
hate
(C
8),
Nov
o-G
esic
C8
(Nov
opha
rm)
0.14
5 0.
184
300
mg
+ 1
5 m
g +
8 m
gffa
blet
A
ceta
zola
mid
e, 2
50 m
gffa
blet
A
po-A
ceta
zola
mid
e (A
pote
x)
Nd
0.79
A
ceta
zola
mid
e, 2
50 m
gffa
blet
D
iam
ox (
Ber
lex)
N
d 1.
0 A
ceta
zola
mid
e, 2
50 m
gffa
blet
N
ovo-
Zol
amid
e (N
ovop
harm
) 0.
100
0.14
3 A
cety
lsal
icyl
ic a
cid,
325
mgf
fabl
et
Nov
asen
Nov
asen
Sp.
C.
(Nov
opha
rm)
0.23
9 N
d A
cety
lsal
icyl
ic a
cid,
650
mgf
fabl
et
Nov
asen
Nov
asen
SP.
C.
(Nov
opha
rm)
0.47
9 N
d A
cycl
ovir
, 40
mg/
mL
/Liq
uid
Zov
irax
(G
laxo
Wel
lcom
e)
1.26
2.
62
Alf
acal
cido
l, 0.
2 m
g/m
L!L
iqui
d O
ne-A
lpha
(L
eo P
harm
a)
2.63
N
d A
lfac
alci
dol,
0.25
mg/
Cap
sule
O
ne-A
lpha
(L
eo P
harm
a)
1.15
N
d ~
Alf
acal
cido
l, 1
mg/
Cap
sule
O
ne-A
lpha
(L
eo P
harm
a)
1.15
N
d -~ A
llop
urin
ol,
100
mgf
fabl
et
Nov
o-P
urol
(N
ovop
harm
) 0.
458
0.48
4 A
llop
urin
ol,
200
mgf
fabl
et
Nov
o-P
urol
(N
ovop
harm
) 0.
057
0.08
4 A
llop
urin
ol,
300
mgf
fabl
et
Nov
o-P
urol
(N
ovop
harm
) 0.
346
0.39
5 A
lpra
zola
m, 0
.25
mgf
fabl
et
Nov
o-A
lpra
zol
(Nov
opha
rm)
0.41
6 0.
450
Alp
razo
lam
, 0.5
0 m
gffa
blet
N
ovo-
Alp
razo
l (N
ovop
harm
) 0.
413
0.48
2 A
lum
iniu
m +
mag
nesi
um h
ydro
xyde
, 45
mg
+ 4
0 m
g!L
iqui
d M
aalo
x (N
ovar
tis
Phar
ma)
N
d 0.
04
Alu
min
ium
+ m
agne
sium
hyd
roxy
de, !
Liq
uid
Alm
agel
(A
tlas
lab
orat
orie
s)
0.20
N
d A
lum
iniu
m h
ydro
xyde
, 64
mg/
mL
!Liq
uid
Am
phog
el (
Axc
an P
harm
a)
Nd
0.60
A
man
tadi
n, 1
0 m
g/m
L!L
iqui
d S
ymm
etre
l (D
u P
ont P
harm
a)
2.58
N
d A
mil
orid
e H
Cl/
Hyd
roch
loro
thia
zide
, 5/
50 m
gffa
blet
N
ovam
ilor
(N
ovop
harm
) 0.
401
0.41
2 A
min
ocap
roic
aci
d, 2
50 m
g/m
L!L
iqui
d A
mic
ar (
Wye
th-A
yers
t)
Nd
2.40
A
mit
ript
ylin
, 10
mgf
fabl
et
Nov
o-T
ript
yn (
Nov
opha
rm)
0.03
9 0.
065
Am
itri
ptyl
in,
25 m
gffa
blet
N
ovo-
Tri
ptyn
(N
ovop
harm
) 0.
046
0.06
3 A
mit
ript
ylin
, 2
mg/
mL
!Liq
uid
Ela
vil
(Mer
ck S
harp
& D
ohm
e)
2.63
N
d
(con
tinue
s)
Tab
le 1
(C
ontin
ued)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n
Am
itri
ptyl
in, 5
0 m
gffa
blet
A
mox
icil
lin
+ cl
avul
anic
aci
d, 5
0+
12.
5 m
g/m
L/L
iqui
d A
mox
icil
lin
+ p
otas
sium
cla
vula
nate
, 25
+ 6
.25
mg/
mL
/Liq
uid
Am
oxic
illi
n +
pot
assi
um c
lavu
lana
te,
250
mg
+ 12
.5 m
gffa
blet
A
mox
icil
lin
+ p
otas
sium
cla
vula
nate
, A
mox
icil
lin,
125
rug
/Che
wab
le t
able
t A
mox
icil
lin,
25
mg/
mL
/Liq
uid
\JJ
Am
oxic
illi
n, 2
5 m
g/m
L/L
iqui
d :;
A
mox
icil
lin,
25
mg/
mL
/Liq
uid
Am
oxic
illi
n, 2
5 m
g/m
L!L
iqui
d A
mox
icil
lin,
25
mg/
mL
/Liq
uid
Am
oxic
illi
n, 2
5 m
g/m
L/L
iqui
d A
mox
icil
lin,
250
mg/
Cap
sule
A
mox
icil
lin,
250
mg/
Cap
sule
A
mox
icil
lin,
250
mg/
Cap
sule
A
mox
icil
lin,
250
mg/
Cap
sule
A
mox
icil
lin,
250
rug
/Che
wab
le ta
blet
A
mox
icil
lin,
50
mg/
mL
/Liq
uid
Am
oxic
illi
n, 5
0 m
g/m
L!L
iqui
d A
mox
icil
lin,
50
mg/
mL
/Liq
uid
Am
oxic
illi
n, 5
0 m
g/m
L/L
iqui
d A
mox
icil
lin,
50
mg/
mL
!Liq
uid
Am
oxic
illi
n, 5
0 m
g/m
L!L
iqui
d
Com
mer
cial
nam
e an
d co
mpa
ny
Nov
o-T
ript
yn (
Nov
opha
rm)
Cla
vuli
n (S
mit
hKli
ne B
eech
am P
harm
a)
Cla
vuli
n (S
mit
hKli
ne B
eech
am P
harm
a)
Cla
vuli
n (S
mit
hKli
ne B
eech
am P
harm
a)
Cla
vuli
n (S
mit
hKli
ne B
eech
am P
harm
a)
Am
oxil
(W
yeth
-Aye
rst)
A
mox
il (
Wye
th-A
yers
t)
Apo
-Am
oxi,
hypo
gluc
idic
(A
pote
x)
Nov
amox
in h
ypog
luci
dic
(Nov
opha
rm)
Nu-
Am
oxi
(Nu-
Pha
rm)
Apo
-Am
oxi
(Apo
tex)
N
ovam
oxin
(N
ovop
harm
) A
mox
il (
Wye
th-A
yers
t)
Apo
-Am
oxi
(Apo
tex)
N
u-A
mox
i (N
u-P
harm
) N
ovam
oxin
(N
ovop
harm
) A
mox
il (
Wye
th-A
yers
t)
Am
oxil
(W
yeth
-Aye
rst)
A
po-A
mox
i, hy
pogl
ucid
ic (
Apo
tex)
N
ovam
oxin
, hy
pogl
ucid
ic (
Nov
opha
rm)
Apo
-Am
oxi
(Apo
tex)
N
u-A
mox
i (N
u-P
harm
) N
ovam
oxin
(N
ovop
harm
)
Cal
oric
con
tent
(kca
l)
Car
bohy
drat
eh
Tota
lb
0.08
2 0.
138
0.18
N
d 0.
18
Nd
1.20
N
d
1.80
N
dO
Nd
0.50
N
d 0.
40
Nd
0.02
6 0.
48
Nd
1.78
N
d 1.
79
Nd
2.27
N
d N
d 0.
20
Nd
0.21
N
d 0.
21
0.08
2 0.
126
Nd
1.0
Nd
0.32
N
d 0.
026
0.41
N
d 1.
78
Nd
1.78
N
d 2.
14
Nd
Am
oxic
illi
n, 5
00 r
ug/C
apsu
le
Am
oxil
(W
yeth
-Aye
rst)
N
d 0.
40
Am
oxic
illi
n, 5
00 r
ug/C
apsu
le
Apo
-Am
oxi
(Apo
tex)
N
d 0.
36
Am
oxic
illi
n, 5
00 r
ug/C
apsu
le
Nu-
Am
oxi
(Nu-
Pha
rm)
Nd
0.36
A
mox
icil
lin,
500
rug
/Cap
sule
N
ovam
oxin
(N
ovop
harm
) 0.
164
0.24
5 A
mpi
cill
in,
100
mg/
mL
/Liq
uid
Nov
o-A
mpi
cill
in (
Nov
opha
rm)
1.87
1.
87
Am
pici
llin
, 25
mg/
mL
/Liq
uid
Apo
-Am
pi (
Apo
tex)
N
d 1.
82
Am
pici
llin
, 25
mg/
mL
/Liq
uid
Nu-
Am
pi (
Nu-
Pha
rm)
Nd
1.82
A
mpi
cill
in,
25 m
g/m
L/L
iqui
d N
ovo-
Am
pici
llin
(N
ovop
harm
) 2.
27
2.27
A
mpi
cill
in,
250
rug/
Cap
sule
A
po-A
mpi
(A
pote
x)
Nd
0.22
A
mpi
cill
in,
250
rug/
Cap
sule
N
u-A
mpi
(N
u-P
harm
) N
d 0.
22
Am
pici
llin
, 25
0 ru
g/C
apsu
le
Nov
o-A
mpi
cill
in (
Nov
opha
rm)
0.10
4 0.
148
Am
pici
llin
, 50
mg/
mL
/Liq
uid
Apo
-Am
pi (
Apo
tex)
N
d 1.
70
Am
pici
llin
, 50
mg/
mL
/Liq
uid
Nu-
Am
pi (
Nu-
Pha
rm)
Nd
1.70
A
mpi
cill
in,
50 m
g/m
L/L
iqui
d N
ovo-
Am
pici
llin
(N
ovop
harm
) 2.
16
2.16
A
mpi
cill
in,
500
rug/
Cap
sule
A
po-A
mpi
(A
pote
x)
Nd
0.39
1.
-. A
mpi
cill
in,
500
rug/
Cap
sule
N
u-A
mpi
(N
u-P
harm
) N
d 0.
39
.....
Vt
Am
pici
llin
, 50
0 ru
g/C
apsu
le
Nov
o-A
mpi
cill
in (
Nov
opha
rm)
0.07
8 0.
155
AS
A-c
affe
ine-
code
ine
phos
phat
e, 1
tabl
et/T
able
t N
ovo
A. C
. &
C.
(Nov
opha
rm)
0.06
7 0.
067
Ate
nolo
l, 1
00 m
gffa
blet
N
ovo-
Ate
nol
(Nov
opha
rm)
0.18
8 0.
222
Ate
nolo
l, 5
0 m
gffa
blet
N
ovo-
Ate
nol
(Nov
opha
rm)
0.09
4 0.
111
Azi
thro
myc
in,
1000
mg/
Pow
der
Zit
hrom
ax (
Pfi
zer)
38
.828
N
d A
zith
rom
ycin
, 20
mg/
mL
/Liq
uid
Zit
hrom
ax (
Pfi
zer)
3.
15
Nd
Azi
thro
myc
in,
250
rug/
Cap
sule
Z
ithr
omax
(P
fize
r)
0.92
8 N
d A
zith
rom
ycin
, 40
mg/
mL
/Liq
uid
Zit
hrom
ax (
Pfi
zer)
3.
16
Nd
Azi
thro
myc
in,
600
mgf
fabl
et
Zit
hrom
ax (
Pfi
zer)
0.
348
Nd
Bac
ampi
cill
in, c
hlor
hydr
ate,
400
mgf
fabl
et
Pen
glob
e (A
stra
Pha
rma)
N
d 0.
10
Bac
ampi
cill
in, c
hlor
hydr
ate,
800
mgf
fabl
et
Pen
glob
e (A
stra
Pha
rma)
N
d 0.
20
Bac
lofe
n, 2
0 m
gffa
blet
N
ovo-
Bac
lofe
n (N
ovop
harm
) 0.
132
0.15
6 B
enzy
dam
ine,
0.1
5 %
/Liq
uid
Nov
o-B
enzy
dam
ine
(Nov
opha
rm)
0.80
8 N
d B
isac
odyl
, 5 r
ug/F
oam
ing
tabl
et
Dul
cola
x (B
oehr
inge
r In
gelh
eim
) N
d 0.
26
(con
tinue
s)
Tab
le 1
(C
onti
nued
)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion
, an
d pr
esen
tati
on
Com
mer
cial
nam
e an
d co
mpa
ny
Car
bohy
drat
eb
Tota
[b
Bis
acod
yl, 5
mg/
Tab
let
Apo
-Bis
acod
yl (
Apo
tex)
N
d 0.
48
Bis
acod
yl,
5 m
g/T
able
t So
flax
EX
(P
harm
asci
ence
) 0.
12
Nd
Bis
mut
h su
bsal
icyl
ate,
17.
6 m
g/m
L/L
iqui
d P
epto
-Bis
mol
(P
roct
er &
Gam
ble)
1.
00
Nd
Bro
maz
epam
, 3
mg/
Tab
let
Nov
o-B
rom
azep
am (
Nov
opha
rm)
0.40
0 0.
417
Bum
etan
ide,
1 m
g/T
able
t B
urin
ex (
Leo
Pha
rma)
0.
61
Nd
Bum
etan
ide,
2 m
g/T
able
t B
urin
ex (
Leo
Pha
rma)
0.
74
Nd
Bum
etan
ide,
5 m
g/T
able
t B
urin
ex (
Leo
Pha
rma)
1.
17
Nd
Bus
piro
ne,
10 m
g/T
able
t N
ovo-
Bus
piro
ne (
Nov
opha
rm)
0.48
7 0.
499
Cal
citr
iol,
1 m
g/m
L/L
iqui
d R
ocal
trol
(R
offm
an-L
a R
oche
) 8.
60
Nd
~
Cal
cium
glu
cona
te +
glu
cohe
pton
ate,
20
mg/
mL
!Liq
uid
Cal
cium
Sta
nley
(St
anle
y P
harm
aceu
tica
ls.)
N
d 0.
04
......
0\
Cal
cium
lact
obio
nate
,/Liq
uid
Cal
cium
-San
doz
(San
doz)
N
d 1.
35
Cal
cium
, 50
0 m
g C
a el
emen
/Cap
sule
C
alsa
n (N
ovar
tis
San
te F
amil
iale
) N
d 5.
85
Cap
topr
il,
100
mg/
Tab
let
Nov
o-C
apto
pril
(N
ovop
harm
) 0.
311
0.32
9 C
apto
pril
, 12
.5 m
g/T
able
t N
ovo-
Cap
topr
il (
Nov
opha
rm)
0.03
9 0.
041
Cap
topr
il, 2
5 m
g/T
able
t N
ovo-
Cap
topr
il (
Nov
opha
rm)
0.07
8 0.
082
Cap
topr
il, 5
0 m
g/T
able
t N
ovo-
Cap
topr
il (
Nov
opha
rm)
0.15
6 0.
165
Car
bam
azep
ine,
100
mg/
Che
wab
le t
able
T
egre
tol (
Nov
arti
s P
harm
a)
Nd
1.08
C
arba
maz
epin
e, 2
0 m
g/m
L/L
iqui
d T
egre
tol
(Nov
arti
s P
harm
a)
Nd
1.79
C
arba
maz
epin
e, 2
00 m
g/T
able
t A
po-C
arba
maz
epin
e (A
pote
x)
Nd
0.35
C
arba
maz
epin
e, 2
00 m
g/T
able
t N
u-C
arba
maz
epin
e (N
u-P
harm
) N
d 0.
35
Car
bam
azep
ine,
200
mg/
Con
trol
led-
rele
ase
tabl
et
Teg
reto
l CR
(Nov
arti
s P
harm
a)
nd
0 C
arba
maz
epin
e, 2
00 m
g/T
able
t T
egre
tol (
Nov
arti
s P
harm
a)
0.00
N
d C
arba
maz
epin
e, 2
00 m
g/T
able
t N
ovo-
Car
bam
az (
Nov
opha
rm)
0.03
1 0.
048
Car
bam
azep
ine,
200
mg/
Con
trol
led-
rele
ase
tabl
et
Teg
reto
l (N
ovar
tis
Pha
rma)
N
d 2.
12
Car
bam
azep
ine,
400
mg/
Con
trol
led-
rele
ase
tabl
et
Teg
reto
l CR
(Nov
arti
s P
harm
a)
Nd
0
Car
niti
ne,
100
mg/
mL
/Liq
uid
Car
nito
r (S
igm
a-T
au P
harm
aceu
tica
ls)
0.20
N
d C
efac
lor,
25
mg/
mL
/Liq
uid
Cec
lor
(Eli
Lil
ly)
Nd
2.52
C
efac
lor,
250
mg/
Cap
sule
P
MS
-Cef
aclo
r (P
harm
asci
ence
) 0.
14
Nd
Cef
aclo
r, 2
50 m
g/C
apsu
le
Apo
-Cef
aclo
r (A
pote
x)
0.28
N
d C
efac
lor,
50
mg/
mL
/Liq
uid
Cec
lor
(Eli
Lil
ly)
Nd
2.42
C
efac
lor,
500
mg/
Cap
sule
P
MS
-Cef
aclo
r (P
harm
asci
ence
) 0.
28
Nd
Cef
aclo
r, 5
00 m
g/C
apsu
le
Apo
-Cef
aclo
r (A
pote
x)
0.31
7 N
d C
efac
lor,
75
mg/
mL
/Liq
uid
Cec
lor
(Eli
Lil
ly)
Nd
2.24
C
efix
ime,
20
mg/
mL
/Liq
uid
Sup
rax
(Rho
ne-P
oule
nc R
orer
) 2.
22
Nd
Cef
ixim
e, 4
00 m
g/T
able
t S
upra
x (R
hone
-Pou
lenc
Ror
er)
0.39
6 N
d C
efpr
ozil
, 25
mg/
mL
/Liq
uid
Cef
zil (
Bri
stol
-Mye
rs S
quib
b)
Nd
1.50
C
efpr
ozil
, 25
0 m
g/T
able
t C
efzi
l (B
rist
ol-M
yers
Squ
ibb)
0.
064
Nd
Cef
proz
il,
50 m
g/m
L/L
iqui
d C
efzi
l (B
rist
ol-M
yers
Squ
ibb)
N
d 1.
30
Cef
proz
il, 5
00 m
g/T
able
t C
efzi
l (B
rist
ol-M
yers
Squ
ibb)
0.
128
Nd
Cef
urox
ime
axet
il,
25 m
g/m
L/L
iqui
d C
efti
n (G
laxo
Wel
lcom
e)
2.45
2.
59
l.iJ
Cef
urox
ime
axet
il,
250
mg/
Tab
let
Cef
tin
(Gla
xo W
ellc
ome)
0.
00
Nd
.....
'-I
Cef
urox
ime
axet
il, 5
00 m
g/T
able
t C
efti
n (G
laxo
Wel
lcom
e)
0.00
N
d C
epha
lexi
n, 2
5 m
g/m
L/L
iqui
d K
efle
x (E
li L
illy
) N
d 2.
48
Cep
hale
xin,
25
mg/
mL
/Liq
uid
Nov
o-L
exin
(N
ovop
harm
) 2.
32
2.32
C
epha
lexi
n, 2
5 m
g/m
L/L
iqui
d P
ms-
Cep
hale
xin
(Pha
rmas
cien
ce)
2.48
N
d C
epha
lexi
n, 2
50 m
g/C
apsu
le
Nov
o-L
exin
(N
ovop
harm
) 0.
044
0.10
9 C
epha
lexi
n, 2
50 m
g/T
able
t A
po-C
epha
lex
(Apo
tex)
N
d 0.
51
Cep
hale
xin,
250
mg/
Tab
let
Nu-
Cep
hale
x (N
u-P
harm
) N
d 0.
51
Cep
hale
xin,
250
mg/
Tab
let
Nov
o-L
exin
(N
ovop
harm
) 0.
075
0.10
4 C
epha
lexi
n, 2
50 m
g/T
able
t P
MS
-Cep
hale
xin
(Pha
rmas
cien
ce)
0.51
N
d C
epha
lexi
n, 5
0 m
g/m
L/L
iqui
d K
efle
x (E
li L
illy
) N
d 2.
42
Cep
hale
xin,
50
mg/
mL
/Liq
uid
Nov
o-L
exin
(N
ovop
harm
) 2.
23
2.23
C
epha
lexi
n, 5
0 m
g/m
L/L
iqui
d P
ms-
Cep
hale
xin
(Pha
rmas
cien
ce)
2.42
N
d C
epha
lexi
n, 5
00 m
g/C
apsu
le
Nov
o-L
exin
(N
ovop
harm
) 0.
088
0.21
1 C
epha
lexi
n, 5
00 m
g/T
able
t A
po-C
epha
lex
(Apo
tex)
N
d 1.
02
(con
tinue
s)
Tab
le 1
(C
ontin
ued)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n C
omm
erci
al n
ame
and
com
pany
C
arbo
hydr
ateh
To
ta[h
Cep
hale
xin,
500
mgt
rabl
et
Nu-
Cep
hale
x (N
u-P
harm
) N
d 1.
02
Cep
hale
xin,
500
mgt
rabl
et
Nov
o-L
exin
(N
ovop
harm
) 0.
150
0.21
3 C
epha
lexi
n, 5
00 m
gtra
blet
P
ms-
Cep
hale
xin
(Pha
rmas
cien
ce)
1.02
N
d C
hlor
al h
ydra
te,
100
mg/
mL
/Liq
uid
Pm
s-C
hlor
alhy
drat
e (P
harm
asci
ence
) 2.
0 N
d C
hlor
al h
ydra
te, 5
00 m
g/C
apsu
le
Nov
o-C
hlor
hydr
ate
(Nov
opha
rm)
0.00
0.
060
Chl
oram
phen
icol
, 25
0 m
g/C
apsu
le
Nov
o-C
hlor
ocap
(N
ovop
harm
) 0.
863
0.93
2 C
hlor
diaz
epox
ide,
10
mg/
Cap
sule
N
ovo-
Pox
ide
SP.C
. (N
ovop
harm
) 0.
465
0.47
6 C
hlor
diaz
epox
ide,
25
mg/
Cap
sule
N
ovo-
Pox
ide
(Nov
opha
rm)
0.41
6 0.
426
Chl
ordi
azep
oxid
e, 5
mg/
Cap
sule
N
ovo-
Pox
ide
(Nov
opha
rm)
0.48
2 0.
492
\jJ
Chl
oroq
uine
, 25
0 m
gtra
blet
N
ovo-
Chl
oroq
uine
(N
ovop
harm
) 0.
824
0.98
8 .....
. 0
0
Chl
orph
enir
amin
e, 4
mgt
rabl
et
Nov
o-P
heni
ram
(N
ovop
harm
) 0.
032
0.05
1 C
hlor
prom
azin
e, 2
0 m
g/m
L/L
iqui
d L
arga
ctil
(R
hone
-Pou
lenc
Ror
er)
2.86
N
d C
hlor
prom
azin
e, 5
mg/
mL
/Liq
uid
Lar
gact
il (
Rho
ne-P
oule
nc R
orer
) 3.
04
Nd
Chl
orpr
omaz
ine,
10
mgt
rabl
et
Nov
o-C
hlor
prom
azin
e (N
ovop
harm
) 0.
064
0.09
4 C
hlor
prom
azin
e, 1
00 m
gtra
blet
N
ovo-
Chl
orpr
omaz
ine
(Nov
opha
rm)
0.21
6 0.
243
Chl
orpr
omaz
ine,
20
mg/
mL
/Liq
uid
Chl
orpr
oman
yl (
Tec
hnila
b)
Nd
3.40
C
hlor
prom
azin
e, 2
00 m
gtra
blet
N
ovo-
Chl
orpr
omaz
ine
(Nov
opha
rm)
0.47
9 0.
568
Chl
orpr
omaz
ine,
25
mgt
rabl
et
Nov
o-C
hlor
prom
azin
e (N
ovop
harm
) 0.
124
0.13
9 C
hlor
prom
azin
e, 4
0 m
g/m
L/L
iqui
d C
hlor
prom
anyl
(T
echn
ilab)
N
d 3.
60
Chl
orpr
omaz
ine,
40
mg/
mL
/Liq
uid
Lar
gact
il (
Rho
ne-P
oule
nc R
orer
) 0.
78
Nd
Chl
orpr
omaz
ine,
50
mgt
rabl
et
Nov
o-C
hlor
prom
azin
e (N
ovop
harm
) 0.
114
0.13
2 C
hlor
prop
amid
e, 2
50 m
gtra
blet
N
ovo-
Pro
pam
ide
(Nov
opha
rm)
0.93
3 0.
978
Chl
orth
alid
one,
100
mgt
rabl
et
Nov
o-T
hali
done
(N
ovop
harm
) 0.
037
0.04
9 C
hlor
thal
idon
e, 5
0 m
gtra
blet
N
ovo-
Tha
lido
ne (
Nov
opha
rm)
0.03
7 0.
049
Cho
lest
yram
ine,
4 g
/dos
e/P
owde
r N
ovo-
Cho
lam
ine
Lig
ht (
Nov
opha
rm)
0.00
0.
00
Cho
lest
yram
ine,
4 g
/dos
e/P
owde
r N
ovo-
Cho
lam
ine
(Nov
opha
rm)
16.0
9 16
.09
Cim
etid
ine,
200
mgf
fabl
et
Nov
o-C
imet
idin
e (N
ovop
harm
) 0.
053
0.07
5 C
imet
idin
e, 3
00 m
gffa
blet
N
ovo-
Cim
etid
ine
(Nov
opha
rm)
0.05
9 0.
093
Cim
etid
ine,
400
mgf
fabl
et
Nov
o-C
imet
idin
e (N
ovop
harm
) 0.
106
0.15
0 C
imet
idin
e, 6
00 m
gffa
blet
N
ovo-
Cim
etid
ine
(Nov
opha
rm)
0.15
9 0.
226
Cim
etid
ine,
800
mgf
fabl
et
Nov
o-C
imet
idin
e (N
ovop
harm
) 0.
211
0.30
1 C
ipro
flox
acin
, 250
mgf
fabl
et
Cip
ro (
Bay
er)
0.17
1 N
d C
ipro
flox
acin
, 500
mgf
fabl
et
Cip
ro (
Bay
er)
0.33
3 N
d C
ipro
flox
acin
, chl
orhy
drat
e, 1
00 m
g/m
L/L
iqui
d C
ipro
(B
ayer
) 6.
40
Nd
Cis
apri
de,
1 m
g/m
L/L
iqui
d P
repu
lsid
(Ja
nsen
-Ort
ho)
0.80
N
d C
lari
thro
myc
in,
250
mgf
fabl
et
Bia
xin
(Abb
ott)
0.
21
Nd
Cla
rith
rom
ycin
, 25
mg/
mL
/Liq
uid
Bia
xin
pedi
atri
c (A
bbot
t)
2.35
N
d C
lari
thro
myc
in,
500
mgf
fabl
et
Bia
xin
(Abb
ott)
0.
00
Nd
Cli
ndam
ycin
, pal
mit
ate,
15
mg/
mL
/Liq
uid
Dal
acin
C (
Pha
rmac
ia &
Upj
ohn)
N
d 1.
20
Clo
baza
m,
10 m
gffa
blet
F
risi
um (
Hoe
chst
Mar
ion
Rou
ssel
) 0.
398
Nd
...,.
Clo
mip
ram
ine
HC
l, 10
mgf
fabl
et
Nov
o-C
lopa
min
e (N
ovop
harm
) 0.
209
0.21
2 -\!;) C
lom
ipra
min
e H
Cl,
25 m
gffa
blet
N
ovo-
Clo
pam
ine
(Nov
opha
rm)
0.00
0.
003
Clo
mip
ram
ine
HC
l, 50
mgf
fabl
et
Nov
o-C
lopa
min
e (N
ovop
harm
) 0.
00
0.00
9 C
lona
zepa
m, 0
.25
mgf
fabl
et
PM
S-C
lona
zepa
m (
Phar
mas
cien
ce)
0.26
N
d C
lona
zepa
m, 0
.5 m
gffa
blet
R
ivot
ril
(Hof
fman
-La
Roc
he)
Nd
0.6
Clo
naze
pam
, 0.5
mgf
fabl
et
PM
S-C
lona
zepa
m (
Phar
mas
cien
ce)
0.13
N
d C
lona
zepa
m,
0.5
mgf
fabl
et
Apo
-Clo
naze
pam
(A
pote
x)
0.48
N
d C
lona
zepa
m,
0.5
mgf
fabl
et
Clo
napa
m (
ICN
) 0.
72
Nd
Clo
naze
pam
, 0.5
mgf
fabl
et
Rho
-Clo
naze
pam
(R
hodi
apha
rm)
0.72
N
d C
lona
zepa
m,
1 m
gffa
blet
P
MS
-Clo
naze
pam
(Ph
arm
asci
ence
) 0.
26
Nd
Clo
naze
pam
, 1.
0 m
gffa
blet
C
lona
pam
(IC
N)
0.72
5 N
d C
lona
zepa
m,
1.0
mgf
fabl
et
Rho
-Clo
naze
pam
(R
hodi
apha
rm)
0.72
5 N
d C
lona
zepa
m,
2 m
gffa
blet
R
ivot
ril
(Hof
fman
-La
Roc
he)
Nd
0.6
Clo
naze
pam
, 2
mgf
fabl
et
PM
S-C
lona
zepa
m (
Phar
mas
cien
ce)
0.54
N
d C
lona
zepa
m,
2 m
gffa
blet
R
ho-C
lona
zepa
m (
Rho
diap
harm
) 0.
722
Nd
(con
tinue
s)
Tab
le 1
(C
onti
nued
)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion
, an
d pr
esen
tati
on
Com
mer
cial
nam
e an
d co
mpa
ny
Car
bohy
drat
eh
Tot a
lb
Clo
naze
pam
, 2.
0 m
gtra
blet
A
po-C
lona
zepa
m (
Apo
tex)
0.
4 N
d C
lona
zepa
m,
2.0
mg!
Tab
let
Clo
napa
m (
ICN
) 0.
722
Nd
Clo
nidi
n, 0
.1 m
gtra
blet
N
ovo-
Clo
nidi
ne (
Nov
opha
rm)
0.41
8 0.
431
Clo
nidi
n, 0
.2 m
gtra
blet
N
ovo-
Clo
nidi
ne (
Nov
opha
rm)
0.79
6 0.
822
Clo
raze
pate
, 15
rug
/Cap
sule
N
ovo-
Clo
pate
(N
ovop
harm
) 0.
601
0.63
2 C
lora
zepa
te,
3.75
rug
/Cap
sule
N
ovo-
Clo
pate
(N
ovop
harm
) 0.
475
0.49
9 C
lora
zepa
te,
7.5
rug/
Cap
sule
N
ovo-
Clo
pate
(N
ovop
harm
) 0.
463
0.48
7 C
loxa
cill
in s
odiu
m,
250
rug/
Cap
sule
A
po-C
loxi
(A
pote
x)
Nd
0.20
C
loxa
cill
in s
odiu
m,
250
rug/
Cap
sule
N
u-C
loxi
(N
u-P
harm
) N
d 0.
21
Vol
C
loxa
cill
in s
odiu
m, 5
00 r
ug/C
apsu
le
Apo
-Clo
xi (
Apo
tex)
N
d 0.
33
N
Clo
xaci
llin
sod
ium
, 500
rug
/Cap
sule
N
u-C
loxi
(N
u-P
harm
) N
d 0.
33
0
Clo
xaci
llin
, 25
mg/
mL
/Liq
uid
Apo
-Clo
xi (
Apo
tex)
N
d 1.
79
Clo
xaci
llin
, 25
mg/
mL
!Liq
uid
Nu-
Clo
xi (
Nu-
Pha
rm)
Nd
1.79
C
loxa
cill
in,
25 m
g/m
L/L
iqui
d O
rben
ine
(Wye
th-A
yers
t)
Nd
2.00
C
loxa
cill
in, 2
5 m
g/m
L/L
iqui
d N
ovo-
Clo
xin
(Nov
opha
rm)
1.80
1.
80
Clo
xaci
llin
, 250
rug
/Cap
sule
O
rben
ine
(Wye
th-A
yers
t)
Nd
0.44
C
loxa
cill
in, 2
50 r
ug/C
apsu
le
Nov
o-C
loxi
n (N
ovop
harm
) 0.
139
0.21
0 C
loxa
cill
in, 5
00 r
ug/C
apsu
le
Orb
enin
e (W
yeth
-Aye
rst)
N
d 0.
30
Clo
xaci
llin
, 50
0 ru
g/C
apsu
le
Nov
o-C
loxi
n (N
ovop
harm
) 0.
00
0.12
3 C
odei
ne, 5
mg/
mL
/Liq
uid
Cod
eine
pho
spha
te (
Rou
gier
) N
d 3.
33
Cyc
lobe
nzap
rine
HC
l, 10
mgt
rabl
et
Nov
o-C
yclo
prin
e (N
ovop
harm
) 0.
533
0.54
2 C
yclo
spor
ine,
100
mg/
mL
/Liq
uid
Neo
ral
(San
doz)
7.
00
Nd
Cyp
rohe
ptad
ine,
0.4
mg/
mL
/Liq
uid
Per
iact
in (
John
son
& J
ohns
on M
erck
con
sum
er
1.80
N
d ph
arm
aceu
tica
ls)
Dap
sone
, 10
0 m
gtra
blet
A
vlos
ulfo
n (W
yeth
-Aye
rst)
N
d 0.
12
Dem
eclo
cycl
ine,
chl
orhy
drat
e, 1
50 m
gffa
blet
D
eclo
myc
in (
Wye
th-A
yers
t)
Nd
1.0
Dem
eclo
cycl
ine,
chl
orhy
drat
e, 3
00 m
gffa
blet
D
eclo
myc
in (
Wye
th-A
yers
t)
Nd
1.0
Des
ipra
min
e H
Cl,
10 m
gffa
blet
N
ovo-
Des
ipra
min
e (N
ovop
harm
) 0.
003
0.00
5 D
esip
ram
ine
HC
l, 25
mgf
fabl
et
Nov
o-D
esip
ram
ine
(Nov
opha
rm)
0.00
7 0.
012
Des
ipra
min
e H
Cl,
50 m
gffa
blet
N
ovo-
Des
ipra
min
e (N
ovop
harm
) 0.
010
0.01
9 D
esip
ram
ine
HC
l, 75
mgf
fabl
et
Nov
o-D
esip
ram
ine
(Nov
opha
rm)
0.01
0 0.
018
Des
oges
trel
-eth
inyl
est
radi
ol, 0
.5 m
gffa
blet
M
arve
lon
(Org
anon
.)
0.28
1 N
d D
esog
estr
el-e
thin
yl e
stra
diol
, 1
mg/
Cap
sule
M
arve
lon
(Org
anon
.)
0.28
1 N
d D
esog
estr
el-e
thin
yl e
stra
diol
, 2 m
g/C
apsu
le
Mar
velo
n (O
rgan
on.)
0.
281
Nd
Dex
amet
haso
ne,
1 m
g/m
L/L
iqui
d P
ms-
Dex
amet
haso
ne (
Pha
rmas
cien
ce)
0.64
N
d D
exam
etha
sone
, 4 m
gffa
blet
D
exas
one
(IC
N)
0.59
1 N
d D
exam
etha
sone
, 50
0 11
gffa
blet
D
exas
one
(IC
N)
0.59
1 N
d D
exam
etha
sone
, 75
0 11
gffa
blet
D
exas
one
(IC
N)
0.58
9 N
d D
extr
omet
horp
han,
bro
rnhy
drat
e, s
ugar
fre
e,
Bal
min
il D
M (
Rou
gier
) 1.
40
Nd
3 m
g/m
L/L
iqui
d .....
D
extr
omet
horp
han,
bro
rnhy
drat
e-ps
eudo
ephe
drin
e-N
ovah
iste
x D
M e
xpec
tora
nt d
econ
gest
ant
2.60
N
d N
-gu
aife
nesi
n, 3
mg
+ 6
mg
+ 2
0 m
g/m
L/L
iqui
d (H
oech
st M
ario
n R
ouss
el)
Dex
trom
etho
rpha
n, b
rorn
hydr
ate-
pseu
doep
hedr
ine,
N
ovah
isti
ne D
M d
econ
gest
ant (
Hoe
chst
Mar
ion
Rou
ssel
) 3.
00
Nd
1.5
mg
+ 3
mg/
mL
/Liq
uid
Dex
trom
etho
rpha
n, b
rom
hydr
ate-
pseu
doep
hedr
ine,
N
ovah
iste
x D
M d
econ
gest
ant
(Hoe
chst
Mar
ion
Rou
ssel
) 2.
40
Nd
3 m
g +
6 m
g/m
L/L
iqui
d D
extr
omet
horp
han,
bro
rnhy
drat
e, 3
mg/
mL
/Liq
uid
Bal
min
il D
M (
Rou
gier
) 2.
40
Nd
Dex
trom
etho
rpha
n, b
rorn
hydr
ate,
3 m
g/m
L/L
iqui
d N
ovah
iste
x D
M (
Hoe
chst
Mar
ion
Rou
ssel
) 2.
40
Nd
Dex
trom
etho
rpha
n, b
rom
hydr
ate-
pseu
doep
hedr
ine-
Nov
ahis
tine
DM
Exp
t Dcg
t (H
oech
st M
ario
n R
ouss
el)
2.44
N
d gu
aife
nesi
n, 1
.5 m
g +
3 m
g +
10
mg/
mL
/Liq
uid
Dex
trom
etho
rpha
n, b
rorn
hydr
ate,
1.5
mg/
mL
ILiq
uid
Nov
ahis
tine
DM
(H
oech
st M
ario
n R
ouss
el)
3.00
N
d D
iaze
pam
, 1
mg/
mL
/Liq
uid
Pm
s-di
azep
am (
Pha
rmas
cien
ce)
1.38
N
d D
iaze
pam
, 10
mgf
fabl
et
Apo
-Dia
zepa
m (
Apo
tex)
N
d 0.
59
Dia
zepa
m,
10 m
gffa
blet
V
aliu
m R
oche
ora
l (R
offm
an-L
a R
oche
) N
d 0.
7 D
iaze
pam
, 10
mgf
fabl
et
Nov
o-D
ipam
(N
ovop
harm
) 0.
692
0.97
4
(con
tinue
s)
Tab
le 1
(C
ontin
ued)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n C
omm
erci
al n
ame
and
com
pany
C
arbo
hydr
ateh
To
talh
Dia
zepa
m,
2 m
gffa
blet
A
po-D
iaze
pam
(A
pote
x)
Nd
0.62
D
iaze
pam
, 2
mgf
fabl
et
Viv
ol (
Car
ter
Hom
er)
Nd
0.4
Dia
zepa
m,
2 m
gffa
blet
N
ovo-
Dip
am (
Nov
opha
rm)
0.71
0 0.
744
Dia
zepa
m,
5 m
gffa
blet
A
po-D
iaze
pam
(A
pote
x)
Nd
0.61
D
iaze
pam
, 5
mgf
fabl
et
Val
ium
Roc
he O
ral
(Hof
fman
-La
Roc
he)
Nd
0.7
Dia
zepa
m,
5 m
gffa
blet
N
ovo-
Dip
am (
Nov
opha
rm)
0.69
5 0.
712
Dic
lofe
nac,
100
mgf
fabl
et
Nov
o-D
ifen
ac S
R (
Nov
opha
rm)
0.87
8 0.
900
Dic
lofe
nac,
25
mgf
fabl
et
Nov
o-D
ifen
ac (
Nov
opha
rm)
0.12
9 0.
135
Dic
lofe
nac,
50
mgf
fabl
et
Nov
o-D
ifen
ac (
Nov
opha
rm)
0.10
9 0.
116
......
Dic
lofe
nac,
75
mgf
fabl
et
Nov
o-D
ifen
ac S
R (
Nov
opha
rm)
0.65
8 0.
675
N
N
Dic
yclo
min
e, 1
0 m
gffa
blet
B
enty
lol (
Hoe
chst
Mar
ion
Rou
ssel
) 0.
369
Nd
Dic
yclo
min
e, 2
mg/
mL
/Liq
uid
Ben
tylo
l (H
oech
st M
ario
n R
ouss
el)
4.00
N
d D
icyc
lom
ine,
20
mgf
fabl
et
Ben
tylo
l (H
oech
st M
ario
n R
ouss
el)
0.36
9 N
d D
iftu
nisa
l, 25
0 m
gffa
blet
N
ovo-
Dif
tuni
sal
(Nov
opha
rm)
0.12
5 0.
155
Dif
tuni
sal,
500
mgf
fabl
et
Nov
o-D
iftu
nisa
l (N
ovop
harm
) 0.
250
0.31
1 D
igox
in, 0
.05
mg/
mL
/Liq
uid
Lan
oxin
(G
laxo
Wel
lcom
e)
1.93
2.
30
Dil
tiaz
em,
120
mgf
fabl
et
Nov
o-D
ilta
zem
SR
(Nov
opha
rm)
0.00
0.
00
Dil
tiaz
em, 3
0 m
gffa
blet
N
ovo-
Dil
taze
m (
Nov
opha
rm)
0.62
3 0.
641
Dil
tiaz
em,
60 m
gffa
blet
N
ovo-
Dil
taze
m S
R (N
ovop
harm
) 0.
00
0.00
D
ilti
azem
, 60
mgf
fabl
et
Nov
o-D
ilta
zem
(N
ovop
harm
) 1.
246
1.28
2 D
ilti
azem
, 90
mgf
fabl
et
Nov
o-D
ilta
zem
SR
(N
ovop
harm
) 0.
00
0.00
D
imen
hydr
inat
e, 1
5 m
gffa
blet
G
ravo
l (C
arte
r H
omer
) N
d 0.
20
Dim
enhy
drin
ate,
15
mg/
Che
wab
le t
able
t G
ravo
l (C
arte
r H
omer
) N
d 1.
40
Dim
enhy
drin
ate,
25
mgf
fabl
et
Gra
vol
(Car
ter
Hom
er)
Nd
0.30
Dim
enhy
drin
ate,
25
mg
imm
edia
te +
50
mg,
con
trol
led
Gra
vol
(Car
ter
Hom
er)
1.20
re
leas
e/C
apsu
le
Dim
enhy
drin
ate,
3 m
g/m
L/L
iqui
d G
ravo
l (C
arte
r H
omer
) N
d 2.
94
Dim
enhy
drin
ate,
3 m
g/m
L!L
iqui
d P
ms-
dim
enhy
drin
ate
(Pha
rmas
cien
ce)
1.5
Nd
Dim
enhy
drin
ate,
50
mgf
fabl
et
Gra
vol
(Car
ter H
omer
) N
d 1.
40
Dim
enhy
drin
ate,
50
rug/
Che
wab
le ta
blet
G
ravo
l (C
arte
r H
omer
) N
d 2.
60
Dip
henh
ydra
min
e, 2
.5 m
g/m
L/L
iqui
d B
enad
ryl e
lixi
r (W
arne
r-L
ambe
rt)
Nd
2.04
D
iphe
nhyd
ram
ine,
2.5
mg/
mL
/Liq
uid
PM
S-d
iphe
nydr
amin
e (P
harm
asci
ence
) 1.
7 N
d D
iphe
nhyd
ram
ine,
6.2
5 m
g/m
L/L
iqui
d B
enad
ryl
(War
ner-
Lam
bert
) N
d 1.
57
Dip
yrid
amol
e, 1
00 m
gffa
blet
N
ovo-
Dip
irad
ol (
Nov
opha
rm)
0.08
8 0.
479
Dip
yrid
amol
e, 2
5 m
gffa
blet
N
ovo-
Dip
irad
ol (
Nov
opha
rm)
0.02
2 0.
153
Dip
yrid
amol
e, 5
0 m
gffa
blet
N
ovo-
Dip
irad
ol (
Nov
opha
rm)
0.04
4 0.
293
Dip
yrid
amol
e, 7
5 m
gffa
blet
N
ovo-
Dip
irad
ol (
Nov
opha
rm)
0.06
6 0.
379
Div
alpr
oex,
sod
ium
, 12
5 m
gffa
blet
E
piva
l (A
bbot
) 0.
08
Nd
Div
alpr
oex,
sod
ium
, 250
mgf
fabl
et
Epi
val
(Abb
ot)
0.17
N
d \j
,l
Div
alpr
oex,
sod
ium
, 500
mgf
fabl
et
Epi
val
(Abb
ot)
0.33
N
d N
\j
,l
Doc
usat
e ca
lciu
m,
240
rug/
Cap
sule
S
urfa
k (H
oech
st M
ario
n R
ouss
el)
0.55
5 N
d D
ocus
ate,
cal
cium
, 24
0 ru
g/C
apsu
le
PM
S-D
ocus
ate
calc
ium
(P
harm
asci
ence
) 1.
00
Nd
Doc
usat
e, c
alci
um, 2
40 r
ug/C
apsu
le
So f
lax
C (
Pha
rmas
cien
ce)
1.00
N
d D
ocus
ate,
sod
ium
+ c
asan
thra
nol,
100
mg
+ 3
0 ru
g/C
apsu
le
Per
i-C
olac
e (R
ober
ts P
harm
aceu
tica
l)
1.00
N
d D
ocus
ate,
sod
ium
+ se
nnos
ides
, 50
mg
+ 8
.6 m
gffa
b1et
S
enok
ot-S
(P
urdu
e F
rede
rick
) N
d 0.
11
Doc
usat
e, s
odiu
m,
10 m
g/m
L/L
iqui
d C
olac
e (R
ober
ts P
harm
aceu
tica
l)
Nd
2.40
D
ocus
ate,
sod
ium
, 10
mg/
mL
/Liq
uid
PM
S-D
ocus
ate,
sod
ium
(P
harm
asci
ence
) 1.
7 N
d D
ocus
ate,
sod
ium
, 10
0 ru
g/C
apsu
le
PM
S-D
ocus
ate,
sod
ium
(P
harm
asci
ence
) 0.
51
Nd
Doc
usat
e, s
odiu
m,
100
rug/
Cap
sule
So
flax
(P
harm
asci
ence
) 0.
51
Nd
Doc
usat
e, s
odiu
m,
100
rug/
Cap
sule
C
olac
e (R
ober
ts P
harm
aceu
tica
l)
1.00
N
d D
ocus
ate,
sod
ium
, 200
rug
/Cap
sule
So
flax
(P
harm
asci
ence
) 0.
51
Nd
Doc
usat
e, s
odiu
m, 4
mg/
mL
/Liq
uid
Doc
usat
e, S
odiu
m (
Tec
hnila
b)
Nd
2.78
D
ocus
ate,
sod
ium
, 4 m
g/m
L/L
iqui
d D
ocus
ate
Sodi
c (T
aro
Pha
rmac
euti
cals
) N
d 2.
40
Doc
usat
e, s
odiu
m, 4
mg/
mL
/Liq
uid
PM
S-D
ocus
ate,
sod
ium
(P
harm
asci
ence
) 1.
7 N
d (c
ontin
ues)
Tab
le 1
(C
ontin
ued)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n C
omm
erci
al n
ame
and
com
pany
C
arbo
hydr
ateb
To
talb
Doc
usat
e, s
odiu
m, 4
mg/
mL
/Liq
uid
Col
ace
(Rob
erts
Pha
rmac
euti
cal)
2.
40
Nd
Doc
usat
e, s
odiu
m, 4
mg/
mL
/Liq
uid
Doc
usat
e, s
odiu
m,
syru
p (A
ltas
) 2.
40
Nd
Doc
usat
e, s
odiu
m,
50 m
g/m
L/L
iqui
d P
ms-
docu
sate
sod
ium
(P
harm
asci
ence
) 1.
05
Nd
Dox
epin
HC
l, 10
0 ru
g/C
apsu
le
Nov
o-D
oxep
ine
(Nov
opha
rm)
0.77
2 0.
819
Dox
epin
HC
l, 15
0 ru
g/C
apsu
le
Nov
o-D
oxep
ine
(Nov
opha
rm)
0.92
3 0.
990
Dox
epin
HC
l, 25
rug
/Cap
sule
N
ovo-
Dox
epin
e (N
ovop
harm
) 0.
428
0.45
2 D
oxep
in H
Cl,
50 r
ug/C
apsu
le
Nov
o-D
oxep
ine
(Nov
opha
rm)
0.69
4 0.
735
Dox
epin
HC
l, 75
rug
/Cap
sule
N
ovo-
Dox
epin
e (N
ovop
harm
) 0.
568
0.60
8 D
oxyc
ycli
ne, h
ycla
te,
100
rug/
Cap
sule
A
po-D
oxy
(Apo
tex)
N
d 0.
74
\.I>
Dox
ycyc
line
, hyc
late
, 10
0 ru
g/C
apsu
le
Nu-
Dox
ycyc
line
(N
u-P
harm
) N
d 0.
74
N
Dox
ycyc
line
, hyc
late
, 10
0 ru
g/C
apsu
le
Nov
o-D
oxyl
in (
Nov
opha
rm)
0.02
2 0.
052
~
Dox
ycyc
line
, hyc
late
, 10
0 ru
g/C
apsu
le
Vib
ram
ycin
(Pf
izer
) 0.
956
Nd
Dox
ycyc
line
, hyc
late
, 10
0 m
gffa
blet
A
po-D
oxy
(Apo
tex)
N
d 0.
44
Dox
ycyc
line
, hyc
late
, 10
0 m
gffa
blet
N
u-D
oxyc
ycli
ne (
Nu-
Pha
rm)
Nd
0.44
D
oxyc
ycli
ne, h
ycla
te,
100
mgf
fabl
et
Vib
ra-T
abs
(Pfi
zer)
0.
516
Nd
Ery
thro
myc
in b
ase,
25
mg/
mL
/Liq
uid
Ery
thro
cin
(Abb
ott)
N
d 1.
96
Ery
thro
myc
in b
ase,
250
rug
/Cap
sule
A
po-E
ryth
ro E
.C.
(Apo
tex)
N
d 0.
20
Ery
thro
myc
in b
ase,
250
rug
/Cap
sule
N
ovo-
Ryt
hro
Enc
ap (
Nov
opha
rm)
0.19
8 N
d E
ryth
rom
ycin
bas
e, 2
50 m
gffa
blet
A
po-E
ryth
ro B
ase
(Apo
tex)
N
d 1.
34
Ery
thro
myc
in b
ase,
250
mgf
fabl
et
Ery
thro
mid
(A
bbot
t)
0.00
N
d E
ryth
rom
ycin
bas
e, 3
33 r
ug/C
apsu
le
Ery
c (P
arke
-Dav
is)
Nd
0.13
E
ryth
rom
ycin
bas
e, 3
33 r
ug/C
apsu
le
Apo
-Ery
thro
E.C
. (A
pote
x)
0.47
3 N
d E
ryth
rom
ycin
bas
e, 3
33 m
gffa
blet
P
CE
(A
bbot
t)
0.64
N
d E
ryth
rom
ycin
bas
e, 5
0 m
g/m
L/L
iqui
d E
ryth
roci
n (A
bbot
t)
Nd
1.84
E
ryth
rom
ycin
bas
e, 5
00 m
gffa
blet
E
rybi
d (A
bbot
t)
0.00
N
d
Ery
thro
myc
in, e
stol
ate
, 25
mg/
ml/
Liq
uid
Ilos
one
(Eli
Lil
ly)
Nd
1.8
Ery
thro
myc
in, e
stol
ate
, 50
mgl
ml/
Liq
uid
Ilos
one
(Eli
Lil
ly)
Nd
1.42
E
ryth
rom
ycin
, est
olat
e, 2
5 m
g/m
L/L
iqui
d N
ovo-
Ryt
hro
esto
late
(N
ovop
harm
) 1.
37
1.37
E
ryth
rom
ycin
, est
olat
e, 2
50 m
g!C
apsu
le
Nov
o-R
ythr
o E
stol
ate
(Nov
opha
rm)
0.26
6 0.
330
Ery
thro
myc
in, e
stol
ate,
50
mg/
mL
/Liq
uid
Nov
o-R
ythr
o es
tola
te (
Nov
opha
rm)
1.37
1.
37
Ery
thro
myc
in,
stea
rate
, 25
mgl
mL
/Liq
uid
Ery
thro
cin
(Abb
ott)
N
d 1.
96
Ery
thro
myc
in,
stea
rate
, 250
mgf
fabl
et
Apo
-Ery
thro
S (
Apo
tex)
N
d 0.
87
Ery
thro
myc
in,
stea
rate
, 250
mgf
fabl
et
Nu-
Ery
thro
myc
in-S
(N
u-P
harm
) N
d 0.
87
Ery
thro
myc
in, s
tear
ate,
250
mgf
fabl
et
Nov
o-R
ythr
o S
tear
ate
(Nov
opha
rm)
0.18
5 1.
846
Ery
thro
myc
in,
stea
rate
, 50
mg/
mL
/Liq
uid
Ery
thro
cin
(Abb
ott)
N
d 1.
84
Ery
thro
myc
in,
stea
rate
, 500
mgf
fabl
et
Apo
-Ery
thro
S (
Apo
tex)
N
d 1.
73
Ery
thro
myc
in,
succ
inat
e, 4
0 m
g/m
L/L
iqui
d E
ES
200
(A
bbot
t)
2.63
N
d E
ryth
rom
ycin
, su
ccin
ate,
600
mgf
fabl
et
Apo
-Ery
thro
-ES
(A
pote
x)
Nd
1.39
E
ryth
rom
ycin
, su
ccin
ate,
600
mgf
fabl
et
EE
S 6
00 (
Abb
ott)
0.
17
Nd
Ery
thro
myc
in,
succ
inat
e, 8
0 m
g/m
L/L
iqui
d E
ES
400
(A
bbot
t)
2.43
N
d ~
Ery
thro
myc
in,
succ
inat
e, 4
0 m
g/m
L/L
iqui
d N
ovo-
Ryt
hro
Eth
yl S
ucci
nate
(N
ovop
harm
) 1.
96
1.96
N
V
l
Ery
thro
myc
in,
succ
inat
e, 8
0 m
g/m
L/L
iqui
d N
ovo-
Ryt
hro
Eth
yl S
ucci
nate
(N
ovop
harm
) 1.
76
1.76
E
ryth
rom
ycin
, su
lfis
oxaz
ole,
40-
120
mg/
mL
/Liq
uid
Ped
iazo
le (
Abb
ott)
N
d 1.
50
Eth
osux
imid
e, 5
0 m
g/m
L/L
iqui
d Z
aron
tin
(Par
ke-D
avis
) N
d 3.
00
Fam
otid
ine,
10
mgf
fabl
et
Nov
o-F
amot
idin
e (N
ovop
harm
) 0.
066
0.07
5 F
amot
idin
e, 2
0 m
gffa
blet
N
ovo-
Fam
otid
ine
(Nov
opha
rm)
0.13
2 0.
149
Fam
otid
ine,
40
mgf
fabl
et
Nov
o-F
amot
idin
e (N
ovop
harm
) 0.
132
0.14
9 F
enof
ibra
te,
100
mg/
Cap
sule
N
ovo-
Feno
fibr
ate
(Nov
opha
rm)
0.55
4 0.
566
Fer
rous
sul
fate
, 15
mg
(ele
men
tal i
ron)
/mL
/Liq
uid
Pm
s-fe
rrou
s su
lfat
e (P
harm
asci
ence
) 2.
71
Nd
Fer
rous
sul
fate
, 15
mg
(ele
men
tal i
ron)
/mL
/Liq
uid
Fer
-In-
Sol
(M
ead
John
son)
2.
76
Nd
Fer
rous
sul
fate
, 30
0 m
gffa
blet
A
po-s
ulfa
te f
erre
ux (
Apo
tex)
N
d 0.
30
Fer
rous
sul
fate
, 30
0 m
gffa
blet
P
MS
-sul
fate
fer
reux
(P
harm
asci
ence
) 0.
57
Nd
Fer
rous
sul
fate
, 6 m
g (e
lem
enta
l iro
n)/m
L/L
iqui
d P
MS
-fer
rous
sul
fate
(P
harm
asci
ence
) 1.
22
Nd
Fer
rous
sul
fate
, 6 m
g (e
lem
enta
l iro
n)/m
L/L
iqui
d F
er-I
n-S
ol (
Mea
d Jo
hnso
n)
5.00
N
d F
luco
nazo
le ,
10 m
g/m
L/L
iqui
d D
iftu
can
(Pfi
zer)
2.
72
Nd
(con
tinue
s)
Tab
le 1
(C
ontin
ued)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n C
omm
erci
al n
ame
and
com
pany
C
arbo
hydr
ateb
To
talb
Flu
nari
zine
HC
l, 5
mg/
Cap
sule
N
ovo-
Flu
nari
zine
(N
ovop
harm
) 0.
576
0.58
3 F
lour
ide,
sod
ium
, 5.
56 m
g/m
L/L
iqui
d F
luor
-A-D
ay (
Pha
rmas
cien
ce)
0 N
d F
luox
etin
e , 4
mg/
mL
!Liq
uid
Pro
zac
(Eli
Lil
ly)
Nd
2.40
F
luox
etin
e, 1
0 m
g/C
apsu
le
Nov
o-F
luox
etin
e (N
ovop
harm
) 0.
730
0.74
7 F
luox
etin
e, 2
0 m
g/C
apsu
le
Nov
o-F
luox
etin
e (N
ovop
harm
) 0.
694
0.71
0 F
luox
etin
e, 4
mg/
mL
!Liq
uid
Apo
-Flu
oxet
ine
(Apo
tex)
3.
64
Nd
Flu
phen
azin
e, 0
.5 m
g/m
L/L
iqui
d P
MS
-Flu
phen
azin
e (P
harm
asci
ence
) 2.
39
Nd
Flu
raze
pam
, 15
mg/
Cap
sule
N
ovo-
Flu
pam
Nov
o-F
lupa
m S
P.C
. (N
ovop
harm
) 1.
193
1.23
6 F
lura
zepa
m,
30 m
g/C
apsu
le
Nov
o-F
lupa
m N
ovo-
Flu
pam
SP.
C.
(Nov
opha
rm)
1.06
0 1.
103
VJ
Flu
rbip
rofe
n, 1
00 m
gffa
blet
N
ovo-
Flu
rpro
fen
(Nov
opha
rm)
0.36
8 0.
401
N
Flu
rbip
rofe
n, 5
0 m
gffa
blet
N
ovo-
Flu
rpro
fen
(Nov
opha
rm)
0.29
9 0.
322
0\
Flu
tam
ide,
250
mgf
fabl
et
Nov
o-F
luta
mid
e (N
ovop
harm
) 1.
249
1.31
1 F
uros
emid
e, 1
0 m
g/m
L!L
iqui
d L
asix
(H
oech
st M
ario
n R
ouss
el)
1.91
3 N
d F
uros
emid
e, 2
0 m
gffa
blet
N
ovo-
Sem
ide
(Nov
opha
rm)
0.17
9 0.
187
Fur
osem
ide,
20
mgf
fabl
et
Las
ix (
Hoe
chst
Mar
ion
Rou
ssel
) 0.
211
Nd
Fur
osem
ide,
40
mgf
fabl
et
Nov
o-S
emid
e (N
ovop
harm
) 0.
360
0.37
7 F
uros
emid
e, 4
0 m
gffa
blet
L
asix
(H
oech
st M
ario
n R
ouss
el)
0.42
0 N
d F
uros
emid
e, 5
00 m
gffa
blet
L
asix
Spe
cial
(H
oech
st M
ario
n R
ouss
el)
0.46
6 N
d F
uros
emid
e, 8
0 m
gffa
blet
N
ovo-
Sem
ide
(Nov
opha
rm)
0.71
9 0.
751
Fur
osem
ide,
80
mgf
fabl
et
Las
ix (
Hoe
chst
Mar
ion
Rou
ssel
) 0.
840
Nd
Fus
idic
aci
d, 2
50 m
gffa
blet
F
ucid
in (
Leo
Pha
rma)
N
d 0.
29
Fus
idic
aci
d, 4
9.2
mg/
ml!
Liq
uid
Fuc
idin
(L
eo P
harm
a)
Nd
0.37
F
usid
ic a
cid,
50
mg/
ml/
Liq
uid
Fuc
idin
(L
eo P
harm
a)
Nd
0.78
G
emfi
broz
il,
300
mg/
Cap
sule
N
ovo-
Gem
fibr
ozil
(N
ovop
harm
) 0.
546
0.56
8 G
emfi
broz
il,
600
mg/
Cap
sule
N
ovo-
Gem
fibr
ozil
(N
ovop
harm
) 0.
205
0.25
9
Gly
buri
de,
2.5
mgf
fabl
et
Nov
o-G
lybu
ride
(N
ovop
harm
) 0.
052
0.05
5 G
lybu
ride
, 5
mgf
fabl
et
Nov
o-G
lybu
ride
(N
ovop
harm
) 0.
103
0.11
0 G
repa
ftox
acin
, chl
orhy
drat
e, 2
00 m
gffa
blet
R
axar
(G
laxo
Wel
lcom
e)
0.00
N
d G
uaif
enes
in,
20 m
g/m
L/L
iqui
d B
alm
inil
E (
Rou
gier
) N
d 1.
60
Gua
ifen
esin
, 20
mg/
mL
/Liq
uid
Bal
min
il E
, su
gar
free
(R
ougi
er)
Nd
1.62
H
alop
erid
ol, 0
.5 m
gffa
blet
N
ovo-
Per
idol
(N
ovop
harm
) 0.
025
0.04
1 H
alop
erid
ol,
1 m
gffa
blet
N
ovo-
Per
idol
(N
ovop
harm
) 0.
025
0.04
1 H
alop
erid
ol,
10 m
gffa
blet
N
ovo-
Per
idol
(N
ovop
harm
) 0.
050
0.08
2 H
alop
erid
ol,
2 m
gffa
blet
N
ovo-
Per
idol
(N
ovop
harm
) 0.
025
0.04
1 H
alop
erid
ol,
2 m
g/m
L/L
iqui
d A
po-H
alop
erid
ol (
Apo
tex)
N
d 0.
01
Hal
oper
idol
, 2 m
g/m
L/L
iqui
d N
ovo-
Per
idol
(N
ovop
harm
) 0.
00
0.00
H
alop
erid
ol, 2
mg/
mL
/Liq
uid
Pm
s-ha
lope
rido
l (P
harm
asci
ence
) 0.
00
0.00
H
alop
erid
ol,
20 m
gffa
blet
N
ovo-
Per
idol
(N
ovop
harm
) 0.
050
0.08
2 H
alop
erid
ol, 5
mgf
fabl
et
Nov
o-P
erid
ol (
Nov
opha
rm)
0.02
5 0.
041
Hyd
rala
zine
HC
l, 10
mgf
fabl
et
Nov
o-H
ylaz
in (
Nov
opha
rm)
0.29
2 0.
301
~
Hyd
rala
zine
, 25
mgf
fabl
et
Nov
o-H
ylaz
in (
Nov
opha
rm)
0.18
2 0.
189
N
-.....)
Hyd
rala
zine
, 50
mgf
fabl
et
Nov
o-H
ylaz
in (
Nov
opha
rm)
0.10
0 0.
106
Hyd
roch
loro
thia
zide
, 25
mgf
fabl
et
Nov
o-H
ydra
zide
(N
ovop
harm
) 0.
238
0.24
7 H
ydro
chlo
roth
iazi
de, 5
0 m
gffa
blet
N
ovo-
Hyd
razi
de (
Nov
opha
rm)
0.47
7 0.
495
Hyd
roch
loro
thia
zide
/met
hyld
opa,
250
+ 1
5 m
gffa
blet
N
ovo-
Dop
aril
-15
(Nov
opha
rm)
0.16
8 0.
211
Hyd
roch
loro
thia
zide
/met
hyld
opa,
250
+ 2
5 m
gffa
blet
N
ovo-
Dop
aril
-25
(Nov
opha
rm)
0.13
5 0.
178
Hyd
rom
orph
one
HC
l, 1
mg/
mL
/Liq
uid
Dil
audi
d (K
noll
) N
d 2.
00
Hyd
rom
orph
one
HC
l, 1
mg/
mL
/Liq
uid
Pm
s-hy
drom
orph
one
(Pha
rmas
cien
ce)
1.09
N
d H
ydro
xyzi
ne, 2
mg/
mL
/Liq
uid
Ata
rax
(Pfi
zer)
N
d 3.
20
Hyd
roxy
zine
, 10
mg/
Cap
sule
A
po-H
ydro
xyzi
ne (
Apo
tex)
N
d 0.
47
Hyd
roxy
zine
, 10
mg/
Cap
sule
N
ovo-
Hyd
roxy
zin
(Nov
opha
rm)
0.00
1.
40
Hyd
roxy
zine
, 2 m
g/m
L/L
iqui
d P
MS
-hyd
roxy
zine
(P
harm
asci
ence
) 2.
37
Nd
Hyd
roxy
zine
, 25
mg/
Cap
sule
A
po-H
ydro
xyzi
ne (
Apo
tex)
N
d 0.
44
Hyd
roxy
zine
, 25
mg/
Cap
sule
N
ovo-
Hyd
roxy
zin
(Nov
opha
rm)
0.00
1.
30
Hyd
roxy
zine
, 50
mg/
Cap
sule
A
po-H
ydro
xyzi
ne (
Apo
tex)
N
d 0.
44
(con
tinue
s)
Tab
le 1
(C
onti
nued
)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n C
omm
erci
al n
ame
and
com
pany
C
arbo
hydr
ateh
To
talh
Hyd
roxy
zine
, 50
mg/
Cap
sule
N
ovo-
Hyd
roxy
zin
(Nov
opha
rm)
0.00
1.
25
Ibup
rofe
n, 2
0 m
g/m
L!L
iqui
d A
dvil
(W
hite
hall
-Rob
ins)
2.
76
Nd
Ibup
rofe
n, 2
00 m
gffa
blet
N
ovo-
Pro
fen
(Nov
opha
rm)
0.18
0 0.
215
Ibup
rofe
n, 2
00 m
gffa
blet
(su
gar
coat
ing)
N
ovo-
Pro
fen
(Nov
opha
rm)
0.25
6 0.
291
Ibup
rofe
n, 3
00 m
gffa
blet
N
ovo-
Pro
fen
(Nov
opha
rm)
0.27
0 0.
322
Ibup
rofe
n, 3
00 m
gffa
blet
(su
gar
coat
ing)
N
ovo-
Pro
fen
(Nov
opha
rm)
0.37
3 0.
425
Ibup
rofe
n, 4
00 m
gffa
blet
N
ovo-
Pro
fen
(Nov
opha
rm)
0.36
0 0.
429
Ibup
rofe
n, 4
00 m
gffa
blet
(su
ger
coat
ing)
N
ovo-
Pro
fen
(Nov
opha
rm)
0.46
3 0.
532
Ibup
rofe
n, 6
00 m
gffa
blet
N
ovo-
Pro
fen
(Nov
opha
rm)
0.54
0 0.
593
\,;>
Im
ipra
min
e, 1
0 m
gffa
blet
N
ovo-
Pra
min
e (N
ovop
harm
) 0.
080
0.08
8 N
0
0
Imip
ram
ine,
25
mgf
fabl
et
Nov
o-P
ram
ine
(N ov
opha
rm)
0.08
0 0.
088
Imip
ram
ine,
50
mgf
fabl
et
Nov
o-P
ram
ine
(Nov
opha
rm)
0.19
5 0.
209
Inda
pam
ide,
2.5
mgf
fabl
et
Nov
o-In
dapa
mid
e (N
ovop
harm
) 0.
255
0.26
0 In
dom
etha
cin,
25
mg/
Cap
sule
N
ovo-
Met
haci
n N
ovo-
Met
haci
n SP
.C.
(Nov
opha
rm)
0.88
7 0.
910
Indo
met
haci
n, 5
0 m
g/C
apsu
le
Nov
o-M
etha
cin
Nov
o-M
etha
cin
SP.C
. (N
ovop
harm
) 1.
458
1.49
5 Is
onia
zid,
10
mg/
mL
/Liq
uid
Pm
s-is
onia
zid
(Pha
rmas
cien
ce)
0.89
N
d Is
osor
bide
din
itra
te,
10 m
gffa
blet
N
ovo-
Sor
bide
(N
ovop
harm
) 0.
160
0.17
4 Is
osor
bide
din
itra
te,
30 m
gffa
blet
N
ovo-
Sor
bide
(N
ovop
harm
) 0.
420
0.44
2 lt
raco
nazo
le,
10 m
g/m
L!L
iqui
d S
pora
nox
(Jan
sen-
Ort
ho)
0.50
N
d K
etoc
onaz
ole,
20
mg/
mL
/Liq
uid
Niz
oral
(J a
nsen
-Ort
ho)
0.25
N
d K
etot
ifen
, fu
mar
ate,
0.2
mg/
mL
!Liq
uid
Apo
-Ket
otif
en (
Apo
tex)
2.
562
Nd
Ket
otif
en,
fum
arat
e, 0
.2 m
g/m
L!L
iqui
d N
ovo-
Ket
otif
en (
Nov
opha
rm)
3.31
3.
31
Ket
otif
en,
fum
arat
e, 1
mgf
fabl
et
Nov
o-K
etot
ifen
(N
ovop
harm
) 0.
493
0.49
9 K
etot
ifen
, fu
mar
ate,
0.2
mg/
mL
!Liq
uid
Zad
iten
(N
ovar
tis
Pha
rma)
2.
41
Nd
Lac
tose
(pl
aceb
o) /
Cap
sule
N
ovo-
Plu
s (N
ovop
harm
) 0.
720
0.73
2
Lac
tulo
se, 6
66.7
mg/
mL
!Liq
uid
Gen
-lac
(G
enph
arm
) N
d 3.
64
Lac
tulo
se, 6
66.7
mg/
mL
/Liq
uid
PM
S-L
actu
lose
(P
harm
asci
ence
) 3.
5 N
d L
amiv
udin
e, 1
0 m
g/m
L!L
iqui
d 3-
TC
(G
laxo
Wel
lcom
e)
1.13
1.
27
Lam
otri
gine
, 10
0 m
g/T
able
t L
amic
tal
(Gla
xo W
ellc
ome)
0.
428
Nd
Lam
otri
gine
, 15
0 m
g/T
able
t L
arni
ctal
(G
laxo
Wel
lcom
e)
0.64
4 N
d L
amot
rigi
ne,
25 m
g/T
able
t L
arni
ctal
(G
laxo
Wel
lcom
e)
0.10
7 N
d L
idoc
aine
, 2%
/Liq
uid
PM
S-L
idoc
aine
, vis
cous
(P
harm
asci
ence
) 0.
2 N
d L
ithi
um, c
arbo
nate
, 60
mg/
mL
/Liq
uid
PM
S-L
ithi
um c
itra
te (
Pha
rmas
cien
ce)
1.77
N
d L
oper
amid
e, 0
.2 m
g/m
L!L
iqui
d P
MS
-Lop
eram
ide
(Pha
rmas
cien
ce)
2.19
N
d L
oper
amid
e, 2
mg/
Tab
let
Nov
o-L
oper
arni
de (
Nov
opha
rm)
1.35
3 1.
383
Lor
atad
ine,
1 m
g/m
L/L
iqui
d C
1ari
tin (
Sch
erin
g)
3.20
N
d L
oraz
epam
, 0.
5 m
g/T
ab1e
t A
po-L
oraz
epam
(A
pote
x)
Nd
0.19
L
oraz
epam
, 0.5
mg/
Tab
let
(sub
ling
ual)
A
tiva
n (W
yeth
-Aye
rst)
N
d 0.
14
Lor
azep
am, 0
.5 m
g/T
able
t N
u-L
oraz
(N
u-P
harm
) N
d 0.
19
Lor
azep
am, 0
.5 m
g/T
able
t N
ovo-
Lor
azem
(N
ovop
harm
) 0.
049
0.04
9 .....
L
oraz
epam
, 1
mg/
Tab
let
Nov
o-L
oraz
em (
Nov
opha
rm)
0.09
8 0.
099
N
\,/;
)
Lor
azep
am,
1.0
mg/
Tab
let
Apo
-Lor
azep
am (
Apo
tex)
N
d 0.
38
Lor
azep
am,
1.0
mg/
Tab
let
(sub
ling
ual)
A
tiva
n (W
yeth
-Aye
rst)
N
d 0.
59
Lor
azep
am,
1.0
mg/
Tab
let
Nu-
Lor
az (
Nu-
Pha
rm)
Nd
0.38
L
oraz
epam
, 2
mg/
Tab
1et
Nov
o-L
oraz
em (
N ov
opha
rm)
0.11
0 0.
112
Lor
azep
am,
2.0
mg/
Tab
let
Apo
-Lor
azep
am (
Apo
tex)
N
d 0.
47
Lor
azep
am,
2.0
mg/
Tab
let
(sub
ling
ual)
A
tiva
n (W
yeth
-Aye
rst)
N
d 0.
19
Lor
azep
am,
2.0
mg/
Tab
let
Nu-
Lor
az (
Nu-
Pha
rm)
Nd
0.47
M
agal
drat
e, 9
6 m
g/m
L/L
iqui
d R
iopa
n (W
hite
hall
-Rob
ins)
0
Nd
Mag
nesi
um, c
itra
te,
15g/
ftac
on!L
iqui
d C
itro
-Mag
(R
ougi
er)
Nd
1.05
M
agne
sium
, hy
drox
ide,
80
mg/
mL
/Liq
uid
Mil
k of
mag
nesi
a (A
tlas
Lab
orat
orie
s)
0 N
d M
apro
tili
ne H
Cl,
10 m
g/T
able
t N
ovo-
Map
roti
line
(N
ovop
harm
) 0.
290
0.29
9 M
apro
tili
ne H
Cl,
50 m
g/T
able
t N
ovo-
Map
roti
line
(N
ovop
harm
) 0.
266
0.27
9 M
apro
tili
ne H
Cl,
75 m
g/T
able
t N
ovo-
Map
roti
line
(N
ovop
harm
) 0.
366
0.38
4 M
edro
xypr
oges
tero
ne a
ceta
te,
10 m
g/T
able
t N
ovo-
Med
rone
(N
ovop
harm
) 0.
428
0.43
3 (c
ontin
ues)
Tab
le 1
(C
onti
nued
)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n C
omm
erci
al n
ame
and
com
pany
C
arbo
hydr
ateb
To
talb
Med
roxy
prog
este
rone
ace
tate
, 2.
5 m
gffa
blet
N
ovo-
Med
rone
(N
ovop
harm
) 0.
380
0.38
4 M
edro
xypr
oges
tero
ne a
ceta
te,
5 m
gffa
blet
N
ovo-
Med
rone
(N
ovop
harm
) 0.
370
0.37
4 M
epro
bam
ate,
200
mgf
fabl
et
Nov
o-M
epro
(N
ovop
harm
) 0.
084
0.11
7 M
epro
bam
ate,
400
mgf
fabl
et
Nov
o-M
epro
(N
ovop
harm
) 0.
168
0.23
5 M
etho
trim
epra
zine
mal
eate
, 25
mgf
fabl
et
Nov
o-M
epra
zine
(N
ovop
harm
) 0.
023
0.03
5 M
etho
trim
epra
zine
mal
eate
, 50
mgf
fabl
et
Nov
o-M
epra
zine
(N
ovop
harm
) 0.
104
0.13
0 M
etho
trim
epra
zine
, 40
mg/
mL
/Liq
uid
Noz
inan
(R
hone
-Pou
lenc
Ror
er)
Nd
1.80
M
etho
trim
epra
zine
, 5
mg/
mL
/Liq
uid
Noz
inan
(R
hone
-Pou
lenc
Ror
er)
Nd
2.98
M
ethy
ldop
a, 1
25 m
gffa
blet
N
ovo-
Med
opa
(Nov
opha
rm)
0.06
0 0.
074
"'" M
ethy
ldop
a, 2
50 m
gffa
blet
N
ovo-
Med
opa
(Nov
opha
rm)
0.11
9 0.
148
"'" M
ethy
ldop
a, 5
00 m
gffa
blet
N
ovo-
Med
opa
(Nov
opha
rm)
0.23
8 0.
297
0
Met
oclo
pram
ide,
1 m
g/m
L/L
iqui
d P
MS
-Met
oclo
pram
ide
(Pha
rmas
cien
ce)
1.3
Nd
Met
oclo
pram
ide,
ch1
orhy
drat
e, 1
mg/
mL
/Liq
uid
Max
eran
(H
oech
st M
ario
n R
ouss
el)
1.96
0 N
d M
etoc
lopr
amid
e, c
hlor
hydr
ate,
10
mgf
fabl
et
Max
eran
(H
oech
st M
ario
n R
ouss
el)
0.36
1 N
d M
etoc
lopr
amid
e, c
hlor
hydr
ate,
5 m
gffa
blet
M
axer
an (
Hoe
chst
Mar
ion
Rou
ssel
) 0.
371
Nd
Met
opro
lol,
100
mgf
fabl
et, c
oate
d N
ovo-
Met
opro
l (N
ovop
harm
) 0.
601
0.63
5 M
etop
rolo
l, 10
0 m
gffa
b1et
, un
coat
ed
Nov
o-M
etop
rol,
unco
ated
(N
ovop
harm
) 0.
601
0.63
1 M
etop
rolo
l, 50
mgf
fabl
et, c
oate
d N
ovo-
Met
opro
l, (N
ovop
harm
) 0.
509
0.53
1 M
etop
rolo
l, 50
mgf
fabl
et,
unco
ated
N
ovo-
Met
opro
l, un
coat
ed (
Nov
opha
rm)
0.30
1 0.
340
Met
roni
dazo
le, 2
50 m
gffa
blet
A
po-M
etro
nida
zole
(A
pote
x)
Nd
0.95
M
etro
nida
zole
, 250
mgf
fabl
et
Nov
o-N
idaz
ole
(Nov
opha
rm)
0.58
5 0.
620
Met
roni
dazo
le, 5
00 m
g/C
apsu
le
Fla
gyl
(Rho
ne-P
oule
nc R
orer
) 0.
00
Nd
Mex
ilet
ine,
chl
orhy
drat
e, 1
00 m
g/G
ranu
les
Nov
o-M
exil
etin
e (N
ovop
harm
) 0.
192
0.20
0 M
exil
etin
e, c
hlor
hydr
ate,
200
mg/
Gra
nule
s N
ovo-
Mex
ilet
ine
(Nov
opha
rm)
0.38
3 0.
401
Min
eral
oil
78%
sug
ar-f
ree
jell
y/Je
lly
Lan
soyl
(Jo
uvei
nal)
N
d 0.
27
Min
eral
oil
78%
gel
/Jel
ly
Lan
soyl
(Jo
uvei
nal)
N
d 0.
60
Min
eral
oil
+ g
lyce
rine
,/Liq
uid
Aga
rol
(War
ner-
Lam
bert
) N
d 0.
65
Min
ocyc
line
, ch
lorh
ydra
te,
100
mg/
Cap
sule
A
po-M
inoc
ycli
ne (
Apo
tex)
N
d 0.
56
Min
ocyc
line
, chl
orhy
drat
e, 1
00 m
g/C
apsu
le
Min
ocin
(W
yeth
-Aye
rst)
N
d 1.
0 M
inoc
ycli
ne, c
hlor
hydr
ate,
50
mg/
Cap
sule
A
po-M
inoc
ycli
ne (
Apo
tex)
N
d 0.
28
Min
ocyc
line
, chl
orhy
drat
e, 5
0 m
g/C
apsu
le
Min
ocin
(W
yeth
-Aye
rst)
N
d 1.
0 M
inoc
ycli
ne, c
hlor
hydr
ate,
100
mg/
Cap
sule
N
ovo-
Min
ocyl
ine
(Nov
opha
rm)
0.60
8 0.
625
Min
ocyc
line
, chl
orhy
drat
e, 5
0 m
g/C
apsu
le
Nov
o-M
inoc
ylin
e (N
ovop
harm
) 0.
524
0.53
6 M
orph
ine,
1 m
g/m
L!L
iqui
d M
orph
itec
-1 (
Tec
hnila
b)
Nd
2.23
M
orph
ine,
1 m
g/m
L/L
iqui
d M
.O.S
. (I
CN
) 0.
21
Nd
Mor
phin
e, 1
0 m
g/m
L!L
iqui
d M
orph
itec
-1 0
(T
echn
ilab)
N
d 2.
23
Mor
phin
e, 1
0 m
g/m
L/L
iqui
d M
.O.S
. (I
CN
) 1.
00
Nd
Mor
phin
e, 2
0 m
g/m
L!L
iqui
d M
orph
itec
-20
(Tec
hnila
b)
Nd
2.23
M
orph
ine,
5 m
g/m
L/L
iqui
d M
orph
itec
-5 (
Tec
hnila
b)
Nd
2.23
M
orph
ine,
5 m
g/m
L/L
iqui
d M
.O.S
. (I
CN
) 1.
17
Nd
\.;.
)
Nad
olol
, 16
0 m
g/T
able
t N
ovo-
Nad
olol
(N
ovop
harm
) 1.
228
1.27
6 \.
;.) - N
adol
ol,
40 m
g/T
able
t N
ovo-
Nad
olol
(N
ovop
harm
) 0.
307
0.32
0 N
adol
ol,
80 m
g/T
able
t N
ovo-
Nad
olol
(N
ovop
harm
) 0.
614
0.63
9 N
apro
xen,
125
mg/
Tab
let
Nov
o-N
apro
x (N
ovop
harm
) 0.
037
0.06
1 N
apro
xen,
25
mg/
mL
/Liq
uid
Nap
rosy
n (R
offm
an-L
a R
oche
) 1.
16
Nd
Nap
roxe
n, 2
50 m
g/T
able
t N
ovo-
Nap
rox
(Nov
opha
rm)
0.07
5 0.
122
Nap
roxe
n, 3
75 m
g/T
able
t N
ovo-
Nap
rox
(Nov
opha
rm)
0.11
2 0.
183
Nap
roxe
n, 5
00 m
g/T
able
t N
ovo-
Nap
rox
(Nov
opha
rm)
0.14
9 0.
245
Nap
roxe
n, s
odiu
m,
275
mg/
Tab
let
Nov
o-N
apro
x, s
odiu
m (
Nov
opha
rm)
0.07
7 0.
135
Nap
roxe
n, s
odiu
m,
550
mg/
Tab
let
Nov
o-N
apro
x, s
odiu
m D
.S.
(Nov
opha
rm)
0.15
4 0.
270
Nit
raze
pam
, 10
mg/
Tab
let
Nit
raza
don
(IC
N)
0.47
N
d N
itra
zepa
m,
10 m
g/T
able
t R
ho-N
itra
zepa
m (
Rho
diap
harm
) 0.
47
Nd
Nit
raze
pam
, 10
mg/
Tab
let
Mog
adon
(R
offm
an-L
a R
oche
) 0.
70
0.80
N
itra
zepa
m,
5 m
g/T
able
t N
itra
zado
n (I
CN
) 0.
233
Nd
Nit
raze
pam
, 5
mg/
Tab
let
Rho
-Nit
raze
pam
(R
hodi
apha
rm)
0.23
3 N
d (c
ontin
ues)
Tab
le 1
(C
onti
nued
)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n C
omm
erci
al n
ame
and
com
pany
C
arbo
hydr
ateh
To
talb
Nit
raze
pam
, 5 m
gffa
blet
M
agad
an (
Hof
fman
-La
Roc
he)
0.35
0.
40
Nit
rofu
rant
oin,
100
mgf
fabl
et
Nov
o-F
uran
(N
ovop
harm
) 0.
146
0.17
2 N
itro
fura
ntoi
n, 5
mg/
mL
/Liq
uid
Nov
o-F
uran
(N
ovop
harm
) 2.
25
2.27
N
itro
fura
ntoi
n, 5
0 ru
g/C
apsu
le
Nov
o-F
uran
toin
Cap
sule
s (N
ovop
harm
) 0.
037
0.03
7 N
itro
fura
ntoi
n, 5
0 m
gffa
blet
N
ovo-
Fur
an (
Nov
opha
rm)
0.07
3 0.
086
Nor
ftox
acin
, 400
mgf
fabl
et
Apo
-Nor
ftox
(A
pote
x)
0.04
4 N
d N
orft
oxac
in, 4
00 m
gffa
blet
N
orox
in (
Mer
ck S
harp
& D
ohm
e)
0.00
N
d N
orm
etha
done
+ep
hedr
ine,
10
mg/
mL
/Liq
uid
Cop
hyla
c (H
oech
st M
ario
n R
ouss
el)
0.80
N
d N
ysta
tin,
100
,000
U/m
L/L
iqui
d N
ils t
at (
Tec
hnil
ab)
3.00
\,
;J
Nys
tati
n, 1
00,0
00 U
/mL
/Liq
uid
Myc
osta
tin
(Bri
stol
-Mye
rs S
quib
b)
2.41
N
d \,
;J
N
Nys
tati
n, 1
00,0
00 U
/mL
/Liq
uid
PM
S-N
ysta
tin
(Pha
rmas
cien
ce)
2.62
N
d N
ysta
tin,
100
,000
IU
/mL
/Liq
uid
Nad
osti
ne (
Lab
orat
oire
Nad
eau)
N
d 2.
60
Nys
tati
n, 1
00,0
00 I
U/m
L/L
iqui
d, s
ugar
fre
e N
ados
tine
(L
abor
atoi
re N
adea
u)
Nd
0.42
N
ysta
tin,
500
,000
IU
ffab
let
Nad
osti
ne (
Lab
orat
oire
Nad
eau)
N
d 0.
43
Nys
tati
n, 5
00,0
00 I
Uff
able
t M
ycos
tati
n (B
rist
ol-M
yers
Squ
ibb)
0.
35
Nd
Oft
oxac
in, 2
00 m
gffa
blet
A
po-O
ftox
(A
pote
x)
0.09
6 N
d O
ftox
acin
, 30
0 m
gffa
blet
A
po-O
ftox
(A
pote
x)
0.15
N
d O
ftox
acin
, 400
mgf
fabl
et
Apo
-Oft
ox (
Apo
tex)
0.
21
Nd
Orc
ipre
nali
ne, 2
mg/
mL
/Liq
uid
Alt
i-O
rcip
rena
llin
e (A
ltim
ed P
harm
aceu
tica
l)
Nd
0.03
6 O
rcip
rena
line
, 2
mg/
mL
/Liq
uid
Apo
-Orc
ipre
nali
ne (
Apo
tex)
1.
99
Nd
Oxa
zepa
m,
10 m
gffa
blet
N
ovox
apam
(N
ovop
harm
) 0.
588
0.61
3 O
xaze
pam
, 15
mgf
fabl
et
Nov
oxap
am (
Nov
opha
rm)
0.56
6 0.
584
Oxt
riph
ylli
ne,
10 m
g/m
L/L
iqui
d C
hole
dyl
(Par
ke-D
avis
) N
d 3.
66
Oxt
riph
ylli
ne,
100
mgf
fabl
et
Nov
o-T
riph
yl (
Nov
opha
rm)
0.10
4 0.
170
Oxt
riph
ylli
ne,
20 m
g/m
L/L
iqui
d C
hole
dyl
(Par
ke-D
avis
) N
d 2.
80
Oxt
riph
ylli
ne, 2
00 m
gffa
blet
N
ovo-
Tri
phyl
(N
ovop
harm
) 0.
134
0.22
0 O
xtri
phyl
line
, 30
0 m
gffa
blet
N
ovo-
Tri
phyl
(N
ovop
harm
) 0.
136
0.22
4 O
xybu
tini
n, l
mg/
mL
/Liq
uid
Apo
-Oxy
buti
nine
(A
pote
x)
2.81
N
d O
xybu
tini
n, l
mg/
mL
/Liq
uid
Dit
ropa
n (P
roct
er &
Gam
ble)
1.
01
Nd
Oxy
buti
nin,
5 m
gffa
blet
N
ovo-
Oxy
buti
nin
(Nov
opha
rm)
0.60
1 0.
616
Pen
icil
lin
G,
500,
000
I.U
.ffa
blet
N
ovo-
Pen
G-5
00 (
Nov
opha
rm)
0.10
4 0.
171
Pen
icil
lin
VK
, 25
mg/
mL
/Liq
uid
Apo
-Pen
VK
(A
pote
x)
Nd
0.81
P
enic
illi
n V
K,
300
mg/
Tab
let
Apo
-Pen
VK
(A
pote
x)
Nd
0.09
P
enic
illi
n V
K,
500,
000
I.U
.ffa
blet
N
ovo-
Pen
VK
(Nov
opha
rm)
0.50
1 0.
573
Pen
icil
lin
VK
, 60
mg/
mL
/Liq
uid
Apo
-Pen
VK
(A
pote
x)
Nd
2.50
P
enic
illi
n V
K, 6
0 m
g/m
L/L
iqui
d N
ovo-
Pen
VK
(N
ovop
harm
) 2.
028
2.11
2 P
eric
yazi
n, 1
0 m
g/m
L/L
iqui
d N
eule
ptil
(R
hone
-Pou
lenc
Ror
er)
Nd
1.00
P
heno
barb
ital
, 10
0 m
g/C
apsu
le
Nov
o-P
ento
barb
(N
ovop
harm
) 0.
227
0.25
4 P
heno
barb
ital
, 15
mgf
fabl
et
Phe
noba
rbit
al (
Park
e-D
avis
) 0.
24
0.24
P
heno
barb
ital
, 30
mgf
fabl
et
Phe
noba
rbit
al (
Park
e-D
avis
) 0.
33
0.33
~
Phe
noba
rbit
al,
5 m
g/m
L/L
iqui
d P
neno
barb
ital
eli
xir
US
P (
Stan
ley
Pha
rmac
euti
cals
.)
3.78
N
d ~
~
Phe
noba
rbit
al, 6
0 m
gffa
blet
P
heno
barb
ital
(Pa
rke-
Dav
is)
0.35
0.
35
Phe
nylb
utaz
one,
100
mgf
fabl
et
Nov
o-B
utaz
one
(Nov
opha
rm)
0.05
3 0.
060
Phe
nyle
phri
ne H
CI-
hydr
ocod
one
bita
rtra
te-g
uaif
enes
in,
Nov
ahis
tex
DH
Exp
t (H
oech
st M
ario
n R
ouss
el)
3.00
N
d 4
mg
+ 1
mg
+ 4
0 m
g/m
L/L
iqui
d P
heny
leph
rine
HC
l-hy
droc
odon
e bi
tart
rate
, N
ovah
isti
ne D
H (
Hoe
chst
Mar
ion
Rou
ssel
) 1.
38
Nd
2 m
g +
0.3
4 m
g/m
L/L
iqui
d P
heny
leph
rine
HC
I-hy
droc
odon
e bi
tart
rate
, N
ovah
iste
x D
H (
Hoe
chst
Mar
ion
Rou
ssel
) 2.
42
Nd
4 m
g +
1 m
g/m
L/L
iqui
d P
heny
leph
rine
HC
l-co
dein
e ph
osph
ate,
N
ovah
iste
x C
(H
oech
st M
ario
n R
ouss
el)
2.22
N
d 4
mg
+ 3
mg/
mL
/Liq
uid
Phe
nyto
in,
sodi
um,
100
mg/
Cap
sule
D
ilan
tin
(Par
ke-D
avis
) 0.
48
0.60
P
heny
toin
, so
dium
, 30
mg/
Cap
sule
D
ilan
tin
(Par
ke-D
avis
) N
d 0.
70
Phe
nyto
in,
25 m
g/m
L/L
iqui
d D
ilan
tin-
125
(Par
ke-D
avis
) 1.
14
Nd
Phe
nyto
in,
50 m
gffa
blet
D
ilan
tin
Infa
tabs
(Pa
rke-
Dav
is)
1.92
N
d (c
ontin
ues)
Tab
le 1
(C
onti
nued
)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n C
omm
erci
al n
ame
and
com
pany
C
arbo
hydr
ateb
To
talb
Pin
dolo
l, 10
mg/
Tab
let
Nov
o-Pi
ndol
(N
ovop
harm
) 0.
055
0.06
3 P
indo
lol,
15 m
g/T
able
t N
ovo-
Pin
dol
(Nov
opha
rm)
0.08
3 0.
094
Pin
dolo
l, 5
mg/
Tab
let
Nov
o-Pi
ndol
(N
ovop
harm
) 0.
050
0.05
6 P
irox
icam
, 1 0
mg/
Cap
sule
N
ovo-
Pir
ocam
(N
ovop
harm
) 1.
056
1.08
6 P
irox
icam
, 20
mg/
Cap
sule
N
ovo-
Pir
ocam
(N
ovop
harm
) 1.
056
1.08
6 P
ivam
pici
llin
, 35
mg/
mL
/Liq
uid
Pon
doci
llin
(L
eo P
harm
a)
1.62
1.
62
Piv
ampi
cill
in,
500
mg/
Tab
let
Pon
doci
llin
(L
eo P
harm
a)
0.43
0.
43
Piv
mec
illi
nam
, chl
orhy
drat
e, 2
00 m
g/T
able
t S
elax
id (
Leo
Pha
rma)
0.
00
Nd
Pol
yeth
ylen
e gl
ycol
/ele
ctro
lyte
s,/L
iqui
d L
ytep
rep
(The
rape
x)
0.00
N
d \j
J
Pol
yeth
ylen
e gl
ycol
/ele
ctro
lyte
s,/L
iqui
d C
olyt
e (R
eed
& C
arnr
ick)
0.
00
Nd
\jJ
>!>-
Pol
yeth
ylen
e gl
ycol
/ele
ctro
lyte
s,/L
iqui
d Pe
gLyt
e (P
harm
asci
ence
) 0.
00
Nd
Pol
yeth
ylen
e gl
ycol
/ele
ctro
lyte
s,/P
owde
r Pe
gLyt
e (P
harm
asci
ence
) 0.
00
Nd
Pol
ysty
rene
sul
fona
te/L
iqui
d N
ovo-
Pra
zin
(Nov
opha
rm)
0.20
2 0.
208
Pra
zoci
n H
CI,
2 m
g/T
able
t N
ovo-
Pra
zin
(Nov
opha
rm)
0.25
3 0.
260
Pra
zoci
n H
Cl,
5 m
g/T
able
t N
ovo-
Pra
zin
(Nov
opha
rm)
0.47
1 0.
484
Pre
dnis
olon
e, 1
mg/
mL
/Liq
uid
Ped
iapr
ed (
Rho
ne-P
oule
nc R
orer
) 2.
26
Nd
Pre
dnis
olon
e, 5
mg/
Tab
let
Nov
o-P
redn
isol
one
(Nov
opha
rm)
0.26
2 0.
273
Pre
dnis
one,
5 m
g/T
able
t N
ovo-
Pre
dnis
one
(Nov
opha
rm)
0.51
0 0.
520
Pre
dnis
one,
50
mg/
Tab
let
Nov
o-P
redn
ison
e (N
ovop
harm
) 0.
586
0.60
6 P
rim
idon
e, 1
25 m
g/C
hew
able
tab
let
Mys
olin
e (W
yeth
-Aye
rst)
N
d 0.
12
Pri
mid
one,
125
mg/
Tab
let
Apo
-Pri
mid
one
(Apo
tex)
N
d 0.
17
Pri
mid
one,
250
mg/
Foa
min
g ta
blet
M
ysol
ine
(Wye
th-A
yers
t)
Nd
0.23
P
rim
idon
e, 2
50 m
g/T
able
t A
po-P
rim
idon
e (A
pote
x)
Nd
0.34
P
roch
lorp
eraz
ine,
1 m
g/m
L/L
iqui
d S
tem
etil
(R
hone
-Pou
lenc
Ror
er)
3.18
N
d P
roch
lorp
eraz
ine,
10
mg/
Tab
let
Ste
met
il (
Rho
ne-P
oule
nc R
orer
) 0
Nd
Pro
chlo
rper
azin
e, 5
mgf
fabl
et
Ste
met
il (
Rho
ne-P
oule
nc R
orer
) 0
Nd
Pro
cycl
idin
e, 0
.5 m
g/m
L/L
iqui
d P
MS
-Pro
cycl
idin
e (P
harm
asci
ence
) 1.
16
Nd
Pro
cycl
idin
e, 0
.5 m
g/m
L/L
iqui
d K
emad
rin
(Gla
xo W
ellc
ome)
2.
30
Nd
Pro
cycl
idin
e, 5
mgf
fabl
et
Kem
adri
n (G
laxo
Wel
lcom
e)
0.47
N
d P
rom
etha
zine
, 2 m
g/m
L/L
iqui
d Pm
s-P
rom
etha
zine
(P
harm
asci
ence
) 1.
8 N
d P
ropo
xyph
ene,
hyd
roch
lori
de, 6
5 ru
g/C
apsu
le
Nov
o-P
ropo
xyn
(Nov
opha
rm)
0.49
1 0.
504
Pro
pran
olol
, 10
mgf
fabl
et
Nov
o-P
rano
l (N
ovop
harm
) 0.
434
0.45
1 P
ropr
anol
ol,
120
mgf
fabl
et
Nov
o-P
rano
l (N
ovop
harm
) 1.
196
1.24
0 P
ropr
anol
ol,
20 m
gffa
blet
N
ovo-
Pra
nol
(Nov
opha
rm)
0.35
2 0.
374
Pro
pran
olol
, 40
mgf
fabl
et
Nov
o-P
rano
l (N
ovop
harm
) 0.
704
0.72
5 P
ropr
anol
ol,
80 m
gffa
blet
N
ovo-
Pra
nol
(Nov
opha
rm)
0.81
9 0.
861
Prp
oxyp
hen
HC
l-A
SA
-caf
fein
e/C
apsu
le
Nov
o-P
ropo
xyn
com
poun
d (N
ovop
harm
) 0.
371
0.39
6 P
seud
oeph
edri
n, 6
mg/
mL
/Liq
uid
Bal
min
il D
econ
gest
ionn
ant (
Rou
gier
) N
d 1.
88
Pse
udoe
phed
rin,
6 m
g/m
L!L
iqui
d P
MS
-Pse
udoe
phed
rine
(P
harm
asci
ence
) 3.
70
Nd
Psy
lliu
m,
no f
lavo
r,/P
owde
r N
ovo-
Muc
ilax
(N
ovop
harm
) 1.
983/
g 1.
983/
g V
>
Psy
lliu
m, s
ugar
fre
e,/P
owde
r N
ovo-
Muc
ilax
(N
ovop
harm
) 0.
000/
g 0.
000/
g V
>
Vl
Psy
lliu
m, o
rang
e fl
avor
/P
owde
r N
ovo-
Muc
ilax
(N
ovop
harm
) 1.
617/
g 1.
617/
g P
syll
ium
, ora
nge,
sm
ooth
tex
ture
/Pow
der
Met
amuc
il (
Pro
cter
& G
ambl
e)
7.76
/g
7.76
/g
Psy
lliu
m (
hydr
ophi
lic
visc
ous
liqu
id f
or o
ral
susp
ensi
on)
Met
amuc
il (
Pro
cter
& G
ambl
e)
3.45
/g
3.45
/g
oran
ge f
lavo
r, sm
ooth
text
ure,
"su
gar
free
" !P
owde
r P
syll
ium
, no
fla
vor,
/Pow
der
Met
amuc
il (
Pro
cter
& G
ambl
e)
1.98
/g
1.98
/g
Psy
lliu
m n
o fl
avor
, su
gar
free
, sm
ooth
text
ure,
/Pow
der
Met
amuc
il (
Pro
cter
& G
ambl
e)
3.45
/g
3.45
/g
Psy
lliu
m +
sene
,/Gra
nule
s P
rodi
em P
lus
(Nov
arti
s)
Nd
0.74
/g
Psy
lliu
m/G
ranu
les
Pro
diem
Sim
ple
(Nov
arti
s)
Nd
0.72
/g
Pyr
ante
l pa
moa
te, 5
0 m
g/m
L/L
iqui
d C
omba
ntri
n (P
fize
r)
3.24
N
d P
yrid
oxin
e hy
droc
hlor
ide,
25
mgf
fabl
et
Vit
amin
B6
(Wam
pole
) 0.
00
Nd
Pyr
vini
um p
amoa
te,
10 m
g/m
L/L
iqui
d V
anqu
in (
War
ner-
Lam
bert
) N
d 0.
90
Qui
nidi
ne, 2
00 m
gffa
blet
N
ovo-
Qui
nidi
ne (
Nov
opha
rm)
0.12
7 0.
228
Qui
nine
, 200
rug
/Cap
sule
N
ovo-
Qui
nine
(N
ovop
harm
) 0.
428
0.53
6 R
anit
idin
e, 1
5 m
g/m
L!L
iqui
d Z
anta
c (G
laxo
Wel
lcom
e)
0.80
0.
83
(con
tinue
s)
Tab
le 1
(C
onti
nued
)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n C
omm
erci
al n
ame
and
com
pany
C
arbo
hydr
ateh
To
talb
Ran
itid
ine,
150
mgf
fabl
et
Nov
o-R
anid
ine
(Nov
opha
rm)
0.00
0.
138
Ran
itid
ine,
150
mgf
fabl
et
Zan
tac
(Gla
xo W
ellc
ome)
0.
01
Nd
Ran
itid
ine,
300
mgf
fabl
et
Nov
o-R
anid
ine
(Nov
opha
rm)
0.00
0.
276
Ran
itid
ine,
300
mgf
fabl
et
Zan
tac
(Gla
xo W
ellc
ome)
0.
01
Nd
Res
erpi
ne,
0.25
mgf
fabl
et
Nov
o-R
eser
pine
(N
ovop
harm
) 0.
607
0.61
3 R
ifam
pin,
150
mg/
Cap
sule
R
ifad
in (
Hoe
chst
Mar
ion
Rou
ssel
) 0.
091
Nd
Rif
ampi
n, 3
00 m
g/C
apsu
le
Rif
adin
(H
oech
st M
ario
n R
ouss
el)
0.18
1 N
d S
albu
tam
ol, 0
.4 m
g/m
L/L
iqui
d V
ento
lin (
Gla
xo W
ellc
ome)
0.
03
0.03
S
albu
tam
ol,
2 m
gffa
blet
N
ovo-
Sal
mol
(N
ovop
harm
) 04
15
0.43
0 \j
.)
Sal
buta
mol
, 4 m
gffa
blet
N
ovo-
Sal
mol
(N
ovop
harm
) 0.
829
0.86
0 \j
.)
Sec
obar
bita
l, so
dium
, 10
0 m
g/C
apsu
le
Nov
o-S
ecob
arb
(Nov
opha
rm)
0.38
5 0.
424
0\
Sel
egil
ine,
5 m
gffa
blet
N
ovo-
Sel
egil
ine
(Nov
opha
rm)
0.48
7 0.
514
Sen
nosi
des,
1. 7
mg/
mL
/Liq
uid
Sen
okot
(P
urdu
e F
rede
rick
) N
d 3.
04
Sen
nosi
des,
15
mg/
5 m
L (3
g)/
Gra
nule
s S
enok
ot (
Pur
due
Fre
deri
ck)
Nd
2.93
/g
Sen
nosi
des,
8.6
mgf
fabl
et
Sen
okot
(P
urdu
e F
rede
rick
) N
d 0.
22
Sen
nosi
des,
119
mg/
sing
le d
ose
(70
mL
)/L
iqui
d X
-Pre
p (P
urdu
e F
rede
rick
) N
d 21
2/70
-mL
bo
ttle
S
enno
side
s, 1
2 m
g/F
oam
ing
tabl
et
Gly
senn
id (
Nov
artis
) N
d 0.
36
Sen
nosi
des,
12
mgf
fabl
et
PM
S-S
enno
side
s (P
harm
asci
ence
) 0.
04
Nd
Sen
nosi
des,
cho
cola
te,
15 m
gffa
blet
E
x-L
ax, c
hoco
late
s pi
eces
(N
ovar
tis)
1.80
N
d S
enno
side
s, 1
5 m
gffa
blet
E
x-L
ax, f
oam
ing
tabl
ets
(Nov
artis
) 0.
74
Nd
Sen
nosi
des,
157
.5 m
g (2
1 g)
/Pow
der
X-P
rep
foam
ing
(Pur
due
Fre
deri
ck)
Nd
38/s
ache
t S
enno
side
s, 2
5 m
gffa
blet
E
x-L
ax E
xtra
-For
t, fo
amin
g ta
blet
s (N
ovar
tis)
0.74
N
d S
enno
side
s, 8
.6 m
g/F
oam
ing
tabl
et
Gly
senn
id (
Nov
artis
) N
d 0.
34
Sen
nosi
des,
8.6
mgf
fabl
et
Pm
s-S
enno
side
s (P
harm
asci
ence
) 0.
06
Nd
Sim
ethi
cone
, 40
mg/
mL
/Liq
uid
Ovo
l (C
arte
r H
omer
) N
d 0.
30
Sod
ium
cit
rate
+ c
itri
c ac
id,
1 m
Eq/
mL
/Liq
uid
PM
S-D
icit
rate
sod
ium
(P
harm
asci
ence
) 0
Nd
Sod
ium
pho
spha
tes,
2.4
g m
onob
asic
+
Fle
et P
hosp
ho-S
oda
(Joh
nson
& J
ohns
on, M
erck
0.
05
Nd
0.9
g di
basi
c/5
mL
/Liq
uid
Con
sum
er P
harm
aceu
tica
ls)
Sod
ium
pho
spha
te 2
.4 g
mon
obas
ic +
P
MS
-Pho
spha
te s
olut
ion
(Pha
rmas
cien
ce)
0.2
Nd
0.9
g di
basi
c/5
mL
/Liq
uid
Sot
alol
HC
I, 80
mgf
fabl
et
Nov
o-S
talo
l (N
ovop
harm
) 0.
241
0.25
3 S
pira
myc
in, 2
50 m
g/C
apsu
le
Rov
amyc
ine
(Rho
ne-P
oule
nc R
orer
) 0.
92
Nd
Spi
ram
ycin
, 500
mg/
Cap
sule
R
ovam
ycin
e (R
hone
-Pou
lenc
Ror
er)
1.84
N
d S
piro
nola
cton
e/hy
droc
hlor
othi
azid
e, 2
5/25
mgf
fabl
et
Nov
o-S
piro
zine
(N
ovop
harm
) 1.
154
1.18
8 S
piro
nola
cton
e/hy
droc
hlor
othi
azid
e, 5
0/50
mgf
fabl
et
Nov
o-S
piro
zine
(N
ovop
harm
) 2.
308
2.37
7 S
piro
nola
cton
e, 1
00 m
gffa
blet
N
ovo-
Spi
roto
n (N
ovop
harm
) 2.
042
2.12
6 S
piro
nola
cton
e, 2
5 m
gffa
blet
N
ovo-
Spi
roto
n (N
ovop
harm
) 0.
895
0.92
9 S
tavu
dine
, 1
mg/
mL
!Liq
uid
Zer
it (
Bri
stol
-Mye
rs S
quib
b)
0.19
5 N
d S
tavu
dine
, 15
mg/
Cap
sule
Z
erit
(B
rist
ol-M
yers
Squ
ibb)
0.
514
Nd
\j,l
Sta
vudi
ne,
20 m
g/C
apsu
le
Zer
it (
Bri
stol
-Mye
rs S
quib
b)
0.77
2 N
d \j
,l
'-I
Sta
vudi
ne, 3
0 m
g/C
apsu
le
Zer
it (
Bri
stol
-Mye
rs S
quib
b)
0.77
2 N
d S
tavu
dine
, 40
mg/
Cap
sule
Z
erit
(B
rist
ol-M
yers
Squ
ibb)
1.
02
Nd
Suc
ralf
ate,
100
0 m
gffa
blet
S
ulcr
ate
(Hoe
chst
Mar
ion
Rou
ssel
) 0.
00
Nd
Suc
ralf
ate,
100
0 m
gffa
blet
N
ovo-
Suc
rala
te (
Nov
opha
rm)
0.14
4 0.
247
Suc
ralf
ate,
200
mg/
mL
/Liq
uid
Sul
crat
e S
uspe
nsio
n P
lus
(Hoe
chst
Mar
ion
Rou
ssel
) 1.
04
Nd
Sul
fapy
ridi
ne,
500
mgf
fabl
et
Dag
enan
(R
hone
-Pou
lenc
Ror
er)
2.05
3 N
d S
ulfi
npyr
azon
e, 1
00 m
gffa
blet
N
ovo-
Pyr
azon
e (N
ovop
harm
) 0.
060
0.08
6 S
ulfi
npyr
azon
e, 2
00 m
gffa
blet
N
ovo-
Pyr
azon
e (N
ovop
harm
) 0.
603
0.62
9 S
ulfi
soxa
zole
, 50
0 m
gffa
blet
N
ovo-
Sox
azol
e (N
ovop
harm
) 0.
518
0.61
6 P
MS
-Sod
ium
Pol
ysty
rene
Sul
fona
te (
Pha
rmas
cien
ce)
0.94
N
d S
ulin
dac,
150
mgf
fabl
et
Nov
o-S
unda
e (N
ovop
harm
) 0.
055
0.09
4 S
ulin
dac,
200
mgf
fabl
et
Nov
o-S
unda
e (N
ovop
harm
) 0.
102
0.12
6 T
emaz
epam
, 15
mg/
Cap
sule
N
ovo-
Tem
azep
am (
Nov
opha
rm)
0.78
1 0.
795
Ten
oxic
am, 2
0 m
gffa
blet
N
ovo-
Ten
oxic
am (
Nov
opha
rm)
0.63
5 0.
645
(con
tinue
s)
Tab
le 1
(C
ontin
ued)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n C
omm
erci
al n
ame
and
com
pany
C
arbo
hydr
ateh
To
talh
Ter
fena
dine
, 12
0 m
gffa
blet
S
elda
ne (
Hoe
chst
Mar
ion
Rou
ssel
) 1.
732
Nd
Ter
fena
dine
, 6 m
g/m
L/L
iqui
d S
elda
ne (
Hoe
chst
Mar
ion
Rou
ssel
) 1.
44
Nd
Ter
fena
dine
, 60
mgf
fabl
et
Sel
dane
(H
oech
st M
ario
n R
ouss
el)
0.19
8 N
d T
erfe
nadi
ne, 6
0 m
gffa
blet
N
ovo-
Ter
fena
dine
(N
ovop
harm
) 1.
453
1.48
3 T
etra
cycl
ine,
25
mg/
mL
/Liq
uid
Nov
o-T
etra
(N
ovop
harm
) 1.
98
1.98
T
etra
cycl
ine,
250
mg/
Cap
sule
N
ovo-
Tet
ra (
Nov
opha
rm)
0.16
3 0.
217
Tet
racy
clin
e, 2
50 m
gffa
blet
N
ovo-
Tet
ra (
Nov
opha
rm)
0.06
4 0.
110
Tet
racy
clin
e, c
hlor
hydr
ate,
250
mg/
Cap
sule
A
po-T
etra
(A
pote
x)
Nd
0.21
T
etra
cycl
ine,
chl
orhy
drat
e, 2
50 m
g/C
apsu
le
Nu-
Tet
ra (
Nu-
Pha
rm)
Nd
0.21
\j
,l
The
ophy
llin
e, 5
.33
mg/
mL
/Liq
uid
The
ophy
llin
e, e
lixi
r (R
ougi
er)
Nd
2.82
\j
,l
The
ophy
llin
e, 5
.33
mg/
mL
/Liq
uid
The
olai
r (3
M P
harm
aceu
tica
l Pro
duct
s)
2.38
N
d 0
0
The
ophy
llin
e an
hydr
ate,
100
mgf
fabl
et
Nov
o-T
heop
hyl
SR
(N
ovop
harm
) 0.
00
0.00
3 T
hior
idaz
ine,
10
mgf
fabl
et
Nov
o-R
idaz
ine
(Nov
opha
rm)
0.19
4 0.
204
Thi
orid
azin
e, 1
00 m
gffa
blet
N
ovo-
Rid
azin
e (N
ovop
harm
) 0.
083
0.11
7 T
hior
idaz
ine,
2 m
g/m
L/L
iqui
d M
ella
ril
Sus
pens
ion
(Nov
arti
s P
harm
a)
2.27
N
d T
hior
idaz
ine,
200
mgf
fabl
et
Nov
o-R
idaz
ine
(Nov
opha
rm)
0.08
0 0.
106
Thi
orid
azin
e, 2
5 m
gffa
blet
N
ovo-
Rid
azin
e (N
ovop
harm
) 0.
082
0.09
3 T
hior
idaz
ine,
30
mg/
mL
/Liq
uid
Mel
lari
l S
olut
ion
(Nov
arti
s P
harm
a)
1.23
N
d T
hior
idaz
ine,
50
mgf
fabl
et
Nov
o-R
idaz
ine
(Nov
opha
rm)
0.10
3 0.
133
Tia
prof
enic
aci
d, 2
00 m
gffa
blet
N
ovo-
Tia
prof
enic
(N
ovop
harm
) 0.
039
0.06
1 T
iapr
ofen
ic a
cid,
300
mgf
fabl
et
Nov
o-T
iapr
ofen
ic (
Nov
opha
rm)
0.05
9 0.
092
Tim
olol
mal
eate
, 10
mgf
fabl
et
Nov
o-T
imol
(N
ovop
harm
) 0.
213
0.22
8 T
imol
ol m
alea
te, 2
0 m
gffa
blet
N
ovo-
Tim
ol (
Nov
opha
rm)
0.42
7 0.
456
Tim
olol
mal
eate
, 5 m
gffa
blet
N
ovo-
Tim
ol (
Nov
opha
rm)
0.10
7 0.
114
Tol
buta
mid
e, 5
00 m
gffa
blet
N
ovo-
But
amid
e SP
.C.
(Nov
opha
rm)
0.52
7 0.
615
Tol
buta
mid
e, 5
00 m
gffa
blet
N
ovo-
But
amid
e (N
ovop
harm
) 0.
532
0.61
3 T
olm
etin
e so
dium
, 400
mg/
Cap
sule
N
ovo-
Tol
met
in (
Nov
opha
rm)
0.30
3 0.
329
Top
iram
ate,
100
mgf
fabl
et
Top
amax
(Ja
nsen
-Ort
ho)
0.64
2 N
d T
opir
amat
e, 2
00 m
gffa
blet
T
opam
ax (
Jans
en-O
rtho
) 0.
350
Nd
Top
iram
ate,
25
mgf
fabl
et
Top
amax
(Ja
nsen
-Ort
ho)
0.16
1 N
d T
raza
done
, 10
0 m
gffa
blet
N
ovo-
Tra
zado
ne (
Nov
opha
rm)
0.60
4 0.
638
Tra
zado
ne,
150
mgf
fabl
et
Nov
o-T
raza
done
(N
ovop
harm
) 0.
147
0.16
3 T
raza
done
, 50
mgf
fabl
et
Nov
o-T
raza
done
(N
ovop
harm
) 0.
301
0.31
8 T
riam
tere
ne/H
ydro
chlo
roth
iazi
de, 5
0/25
mgf
fabl
et
Nov
o-T
riam
zide
(N
ovop
harm
) 0.
060
0.09
1 T
riaz
olam
, 0.1
25 m
gffa
blet
N
ovo-
Tri
o lam
(N
ovop
harm
) 0.
312
0.32
0 T
riaz
olam
, 0.2
5 m
gffa
blet
N
ovo-
Tri
o lam
(N
ovop
harm
) 0.
310
0.31
9 T
rifl
uope
razi
ne,
1 m
gffa
blet
N
ovo-
Flu
razi
ne (
Nov
opha
rm)
0.26
7 0.
278
Tri
fluo
pera
zine
, 10
mgf
fabl
et
Nov
o-F
lura
zine
(N
ovop
harm
) 0.
520
0.54
2 T
rifl
uope
razi
ne,
10 m
g/m
L/L
iqui
d P
MS
-tri
fluo
pera
zine
(P
harm
asci
ence
) 2.
6 N
d T
rifl
uope
razi
ne, 2
mgf
fabl
et
Nov
o-F
lura
zine
(N
ovop
harm
) 0.
387
0.40
3 ~
Tri
fluo
pera
zine
, 20
mgf
fabl
et
Nov
o-F
lura
zine
(N
ovop
harm
) 0.
523
0.54
5 ~
\0
Tri
fluo
pera
zine
, 5
mgf
fabl
et
Nov
o-F
lura
zine
(N
ovop
harm
) 0.
430
0.44
7 T
rihe
xyph
enid
yl, 0
.4 m
g/m
L/L
iqui
d P
ms
trih
exyp
heni
dyl
(Pha
rmas
cien
ce)
2.02
N
d T
rihe
xyph
enid
yl, 2
mgf
fabl
et
Nov
o-H
exid
yl (
Nov
opha
rm)
0.05
6 0.
076
Tri
hexy
phen
idyl
, 5 m
gffa
blet
N
ovo-
Hex
idyl
(N
ovop
harm
) 0.
115
0.15
5 T
rim
epra
zin,
0.5
mg/
mL
/Liq
uid
Pan
ecty
l 2.5
(R
hone
-Pou
lenc
Ror
er)
3.22
N
d T
rim
etho
prim
, 10
0 m
gffa
blet
P
rolo
prim
(G
laxo
Wel
lcom
e)
0.52
N
d T
rim
etho
prim
, 20
0 m
gffa
blet
P
rolo
prim
(G
laxo
Wel
lcom
e)
0.12
N
d T
rim
etho
prim
+ su
lfam
etho
xazo
le,
160/
800
mgf
fabl
et
Apo
-Sul
fatr
im D
S (A
pote
x)
Nd
0.30
T
rim
etho
prim
+ su
lfam
etho
xazo
le,
160/
800
mgf
fabl
et
Bac
trim
Roc
he (
Rof
fman
-La
Roc
he)
Nd
0.40
T
rim
etho
prim
+ su
lfam
etho
xazo
le,
160/
800
mgf
fabl
et
Nu-
Cot
rim
ox (
Nu-
Pha
rm)
Nd
0.30
T
rim
etho
prim
+ su
lfam
etho
xazo
le,
160/
800
mgf
fabl
et
Sep
tra
DS
(Gla
xo W
ellc
ome)
N
d 0.
08
Tri
met
hopr
im +
sulf
amet
hoxa
zole
, 16
0/80
0 m
gffa
blet
N
ovo-
Tri
mel
(N
ovop
harm
) 0.
325
0.47
0 T
rim
etho
prim
+ su
lfam
etho
xazo
le, 2
0110
0 m
gffa
blet
A
po-S
ulfa
trim
(A
pote
x)
Nd
0.04
pe
diat
ric
Tri
met
hopr
im +
sulf
amet
hoxa
zole
, 8/
40 m
g/m
L/L
iqui
d A
po-S
ulfa
trim
(A
pote
x)
Nd
2.47
(c
onti
nues
)
Tab
le 1
(C
onti
nued
)
Cal
oric
con
tent
(kca
l)
Dru
g, c
once
ntra
tion,
and
pre
sent
atio
n C
omm
erci
al n
ame
and
com
pany
C
arbo
hydr
ateh
To
tal"
Tri
met
hopr
im +
sul
fam
etho
xazo
le,
8/40
mg/
mL
/Liq
uid
Nu-
Cot
rim
ox (
Nu-
Pha
rm)
Nd
2.47
T
rim
etho
prim
+ s
ulfa
met
hoxa
zole
, 8/
40 m
g/m
L/L
iqui
d S
eptr
a (G
laxo
Wel
lcom
e)
Nd
2.60
T
rim
etho
prim
+ s
ulfa
met
hoxa
zole
, 8/
40 m
g/m
L/L
iqui
d N
ovo-
Tri
mel
(N
ovop
harm
) 0.
011
0.01
1 T
rim
etho
prim
+ s
ulfa
met
hoxa
zole
, 8/
40 m
g/m
L/L
iqui
d B
actr
im R
oche
(R
offm
an-L
a R
oche
) 1.
81
2.42
T
rim
etho
prim
+ s
ulfa
met
hoxa
zole
, 80
/400
mg/
Tab
let
Apo
-Sul
fatr
im (
Apo
tex)
N
d 0.
15
Tri
met
hopr
im +
sul
fam
etho
xazo
le,
80/4
00 m
g/T
able
t B
actr
im R
oche
(R
offm
an-L
a R
oche
) N
d 0.
20
Tri
met
hopr
im +
sul
fam
etho
xazo
le,
80/4
00 m
g/T
able
t N
u-C
otri
mox
(N
u-P
harm
) N
d 0.
15
Tri
met
hopr
im +
sulf
amet
hoxa
zole
, 80
/400
mg/
Tab
let
Sep
tra
(Gla
xo W
ellc
ome)
N
d 0.
04
Tri
met
hopr
im +
sul
fam
etho
xazo
le,
80/4
00 m
g/T
able
t N
ovo-
Tri
mel
(N
ovop
harm
) 0.
163
0.23
5 \.
).)
Tri
mip
ram
ine,
mal
eate
, 10
0 m
g/T
able
t N
ovo-
Tri
pram
ine
(Nov
opha
rm)
0.04
6 0.
067
>!>--
0 T
rim
ipra
min
e, m
alea
te,
25 m
g/T
able
t N
ovo-
Tri
pram
ine
(Nov
opha
rm)
0.01
2 0.
017
Tri
mip
ram
ine,
mal
eate
, 50
mg/
Tab
let
Nov
o-T
ripr
amin
e (N
ovop
harm
) 0.
023
0.03
3 T
rova
flox
acin
, 10
0 m
g/T
able
t T
rova
n (P
fize
r)
0.38
8 N
d T
rova
flox
acin
, 200
mg/
Tab
let
Tro
van
(Pfi
zer)
0.
780
Nd
Val
proi
c ac
id,
250
rug/
Cap
sule
D
epak
ene
(Abb
ott)
0.
00
Nd
Val
proi
c ac
id,
250
rug/
Cap
sule
P
MS
-Val
proi
c A
cid
(Pha
rmas
cien
ce)
0.71
N
d V
alpr
oic
acid
, 25
0 ru
g/C
apsu
le
Nov
o-V
alpr
oic
(Nov
opha
rm)
0.90
N
d V
alpr
oic
acid
, 50
mg/
mL
/Liq
uid
Alt
i-V
alpr
oic
(Alt
iMed
) N
d 3.
54
Val
proi
c ac
id,
50 m
g/m
L/L
iqui
d P
MS
-Val
proi
c ac
id (
Pha
rmas
cien
ce)
2.8
Nd
Val
proi
c ac
id,
500
rug/
Cap
sule
D
epak
ene
(Abb
ot)
0.00
N
d V
alpr
oic
acid
, 50
0 ru
g/C
apsu
le
PM
S-V
alpr
oic
acid
E.C
. (P
harm
asci
ence
) 0.
00
Nd
Val
proi
c ac
id,
500
rug/
Cap
sule
P
MS
-Val
proi
c ac
id (
Pha
rmas
cien
ce)
0.71
N
d V
alpr
oic
acid
, 50
0 ru
g/C
apsu
le
Nov
o-V
alpr
oic
(Nov
opha
rm)
0.88
N
d V
alpr
oic
acid
, 50
mg/
mL
/Liq
uid
Dep
aken
e (A
bbot
t)
2.97
3.
54
Ver
apam
il,
120
mg/
Tab
let
Nov
o-V
eram
il (N
ovop
harm
) 0.
083
0.09
6
Ver
apam
il,
80 m
g!fa
blet
N
ovo-
Ver
amil
(Nov
opha
rm)
0.05
5 0.
064
Vig
abat
, 50
0 m
gffa
blet
S
abri
l (H
oech
st M
ario
n R
ouss
el)
0.05
6 0.
579
Vit
amin
A B
C D
/Liq
uid
Infa
ntol
Dro
ps (
Car
ter
Hom
er)
Nd
2.8
Vit
amin
A B
C D
!Liq
uid
Infa
ntol
Liq
uid
(Car
ter
Hom
er)
Nd
l.l6
V
itam
in A
B C
D/L
iqui
d P
olyv
isol
(M
ead
John
son)
3.
40
Nd
Vit
amin
A C
D/L
iqui
d T
ri-v
i-so
l (M
ead
John
son)
2.
20
Nd
Vit
amin
A C
D +
fluo
rine
,/Liq
uid
Tri
-vi-
flor
(M
ead
John
son)
2.
20
Nd
Vit
amin
A C
D +
fluo
rine
,/Liq
uid
Tri
-vi-
sol
wit
h fl
uori
ne (
Mea
d Jo
hnso
n)
2.20
N
d V
itam
in D
, 40
0 U
/mL
/Liq
uid
D-v
i-so
l400
U/0
.6 m
L (
Mea
d Jo
hnso
n)
2.20
N
d V
itam
in E
, 50
U/m
L/L
iqui
d A
quas
ol E
(N
ovar
tis)
1.
52
Nd
Vit
amin
E,
100
IU/C
apsu
le
Aqu
asol
E (
Nov
arti
s)
1.44
N
d V
itam
in E
, 40
0 IU
/cap
sule
V
itam
in E
(S
ante
Nat
urel
le A
drie
n G
agno
n)
0.29
N
d V
itam
ins,
mul
ti-,
/Cap
sule
Fo
rtam
ines
-1 0
Cap
sule
(R
ougi
er)
0.36
N
d V
itam
ins,
mul
ti-,
!fab
let
Fort
amin
es-1
0 (
Rou
gier
) 0.
36
Nd
Vit
amin
s, m
ulti
-,!f
able
t M
axi-
10 (
Rou
gier
) 0.
36
Nd
\.;>
Z
idov
udin
e, I
00
rug/
Cap
sule
N
ovo-
AZ
T (
Nov
opha
rm)
0.06
0 0.
074
~ -
" T
he c
alor
ic c
onte
nt i
ndic
ated
is f
or 1
mL
, one
tabl
et, o
r on
e ca
psul
e un
less
oth
erw
ise
indi
cate
d.
h N
d =
No
dat
a. W
hen
no d
ata
are
avai
labl
e fo
r ca
lori
c co
nten
t pro
vide
d by
car
bohy
drat
es, w
e su
gges
t the
use
of t
otal
Cal
oric
con
tent
.
Tab
le 2
W
orst
-Cas
e Sc
enar
io S
tudy
Dat
a
Cal
oric
A
ctiv
e E
xcip
ient
co
nten
t, C
alor
ic
ingr
edie
nt
Wei
ght
wei
ght
esti
mat
ed
cont
ent
Diff
eren
ce
Med
icat
iona
F
orm
ulat
ion
(mg)
(g
) (g
) (k
cal)
(k
cal)
(k
cal)
Bia
xin
Tab
let
250
0.51
96
0.26
96
1.07
84
0.21
0 0.
868
Cip
ro
Tab
let
250
0.38
05
0.13
05
0.52
2 0.
171
0.35
1 E
piva
l T
able
t 25
0 0.
4975
0.
2475
0.
99
0.17
0 0.
820
Lam
ie ta
l T
able
t 25
0.
0802
0.
0552
0.
2208
0.
107
0.11
4 N
ovam
oxin
C
apsu
le
250
0.38
24
0.13
24
0.52
96
0.08
2 0.
448
Nov
amox
in
Cap
sule
50
0 0.
7052
0.
2052
0.
8208
0.
164
0.65
7 N
ovo-
Car
bam
az
Tab
let
200
0.25
68
0.05
68
0.22
72
0.03
1 0.
196
Nov
o-C
hlor
ocap
C
apsu
le
250
0.55
57
0.30
57
1.22
28
0.86
3 0.
360
:t. N
ovo-
Chl
oroq
uine
T
able
t 25
0 0.
7868
0.
5368
2.
1472
0.
824
1.32
3 N
N
ovo-
Chl
orpr
omaz
ine
Tab
let
100
0.39
22
0.29
22
1.16
88
0.21
6 0.
953
Nov
o-C
loxi
n C
apsu
le
250
0.38
84
0.13
84
0.55
36
0.13
9 0.
415
Nov
o-C
loxi
n C
apsu
le
500
0.66
28
0.16
28
0.65
12
0.00
0 0.
651
Nov
o-D
ipir
adol
T
able
t 50
0.
1844
0.
1344
0.
5376
0.
044
0.49
4 N
ovo-
Dox
epin
C
apsu
le
25
0.19
87
0.17
37
0.69
48
0.42
8 0.
267
Nov
o-D
oxy l
in
Cap
sule
10
0 0.
3478
0.
2478
0.
9912
0.
022
0.96
9 N
ovo-
Fur
an
Tab
let
50
0.17
84
0.12
84
0.51
36
0.07
3 0.
441
Nov
o-H
ydra
zide
T
able
t 25
0.
1047
0.
0797
0.
3188
0.
238
0.08
1 N
ovo-
Hyd
roxy
zin
Sof
t gel
atin
10
0.
229
0.21
9 0.
876
0.00
0 0.
876
Nov
o-H
ylaz
in
Tab
let
25
0.15
22
0.12
72
0.50
88
0.18
2 0.
327
Nov
o-L
exin
T
able
t 25
0 0.
3622
0.
1122
0.
4488
0.
075
0.37
4 N
ovo-
Met
haci
n C
apsu
le
25
0.29
9 0.
274
1.09
6 0.
887
0.20
9 N
ovo-
Nap
rox
Tab
let
250
0.36
95
0.11
95
0.47
8 0.
075
0.40
3 N
ovo-
Nid
azol
T
able
t 25
0 0.
5395
0.
2895
1.
158
0.58
5 0.
573
Nov
o-P
erid
ol
Tab
let
2 0.
1258
0.
1238
0.
4952
0.
025
0.47
0
Nov
o-P
heni
ram
T
able
t 4
0.21
98
0.21
58
0.86
32
0.03
2 0.
831
Nov
o-P
iroc
am
Cap
sule
10
0.
3959
0.
3859
1.
5436
1.
056
0.48
8 N
ovo-
Pra
nol
Tab
let
10
0.13
45
0.12
45
0.49
8 0.
434
0.06
4 N
ovo-
Pre
dnis
one
Tab
let
50
0.21
8 0.
168
0.67
2 0.
586
0.08
6 N
ovo-
Pur
ol
Tab
let
100
0.29
89
0.19
89
0.79
56
0.45
8 0.
338
Nov
o-R
ythr
o E
stol
ate
Cap
sule
25
0 0.
5589
0.
3089
1.
2356
0.
266
0.97
0 N
ovo-
Sem
ide
Tab
let
40
0.16
48
0.12
48
0.49
92
0.36
0 0.
139
Nov
o-S
piro
ton
Tab
let
25
0.26
2 0.
237
0.94
8 0.
895
0.05
3 N
ovo-
Spi
roto
n T
able
t 10
0 0.
6475
0.
5475
2.
19
2.04
2 0.
148
N ov
o-S
ucr
alat
e T
able
t 10
00
1.19
0.
19
0.76
0.
144
0.61
6 N
ovo-
Tet
ra
Cap
sule
25
0 0.
3566
0.
1066
0.
4264
0.
163
0.26
3 N
ovo-
Tri
mel
T
able
t 48
0 0.
5284
0.
0484
0.
1936
0.
163
0.03
1 N
ovo-
Tri
ptyn
T
able
t 50
0.
239
0.18
9 0.
756
0.08
2 0.
674
Nov
o-V
eram
il
Tab
let
80
0.28
08
0.20
08
0.80
32
0.05
5 0.
748
Nov
o-Z
olam
ide
Tab
let
250
0.49
77
0.24
77
0.99
08
0.10
0 0.
891
e P
heno
barb
ital
T
able
t 15
0.
081
0.06
6 0.
264
0.24
0 0.
024
Phe
noba
rbit
al
Tab
let
30
0.12
07
0.09
07
0.36
28
0.33
0 0.
033
Pm
s-S
odiu
m D
ocus
ate
Cap
sule
10
0 0.
4355
0.
3355
1.
342
0.51
0 0.
832
Rif
adin
S
oft g
elat
in
300
0.42
44
0.12
44
0.49
76
0.18
1 0.
317
Vig
abat
rin
Tab
let
500
0.67
89
0.17
89
0.71
56
0.05
6 0.
660
Ste
met
il
Tab
let
5 0.
0822
0.
0772
0.
3088
0.
000
0.30
9 V
itam
in E
(A
drie
n G
agno
n)
Cap
sule
29
4 0.
5862
0.
2922
1.
1688
0.
290
0.87
9
" B
rand
nam
es.
344
Table 3 Differences in Caloric Content of Similar Drug Preparations in Canada and the United States
Appendix A
Drugs Caloric content (Canada) Caloric content (US)
Acetaminophen (syrup) 1.78 kcal/mL 1.8 kcal/mL Acetaminophen (325-mg tablet) 0.2 kcal/tablet 0.16 kcal!tablet Carbamazepine (syrup) 1. 79 kcallmL 2.68 kcal/mL Carbamazepine (200-mg tablet) 0.35 kcalltablet 0.205 kcal/tablet Phenytoin (syrup) 1.14 kcal/mL 0.832 kcal!mL Phenytoin (30-mg capsule) 0. 7 kcal/capsule 0.6 kcal/capsule Valproic acid (syrup) 3.54 kcal/mL 3.456 kcal!mL
Finally, as shown in Table 3, the caloric content of these formulations may vary from country to country ( 4 ). We believe that a comprehensive table should be developed in each country and updated every 5 yr.
REFERENCES
1. Huttenlocher PR. Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy. Pediatr Res 1976;10:419-423.
2. Wheless JW. The ketogenic diet: fa(c)t or fiction. J Child Neuroll995;10:419-423. 3. Lebel D, Morin C, Laberge M, Achim N, Carmant L. The carbohydrate and caloric content of concomi
tant medications for children with epilepsy on the ketogenic diet. Can J Neurol Sci 2001;28:322-340. 4. Feldstein TJ. Carbohydrate and alcohol content of 200 oral liquid medications for use in patients receiv
ing ketogenic diets. Pediatrics 1996:97:506-511.
Appendix B Ketogenic Diet Resources
Carl E. Stafitrom and ]ong M Rho
PUBLICATIONS
Books Freeman JM, Freeman JB, Kelly MT (2000) The Ketogenic Diet: A Treatment for Epilepsy, 3rd edition Demos Publications, New York Phone: (212) 683-0072
Freeman JM, Vining EPG, Pillas D (1990) Seizures and Epilepsy in Childhood: A Guide for Parents Johns Hopkins University Press, Baltimore
Pennington J ( 1994) Bowes and Church's Food Values and Portions Commonly Used, 16th edition JB Lippincott, Philadelphia
Keto Klub Newsletter To receive or contribute, write to: Keto Klub 61557 Miami Meadows Court South Bend, IN 46614
Low-Carb Cookery A book of low-carbohydrate recipes The author, Alex Haas, can be contacted at [email protected]
ORGANIZATIONS
The Charlie Foundation The Charlie Foundation to Help Cure Pediatric Epilepsy 1223 Wilshire Blvd #815 Santa Monica, CA 90403-5406 310-395-6751 Educational and informational videotapes about the diet available by calling: 1-800-367-5386
From: Nutrition and Health Epilepsy and the Ketogenic Diet
Edited by: C. E. Stafstrom and J. M. Rho© Humana Press Inc., Totowa, NJ
345
346 Appendix B
The Epilepsy Foundation of America Information and advocacy for persons with epilepsy 4351 Garden City Dr. Landover, MD 20785 800-332-1000 http://www.epilepsyfoundation.org/
American Epilepsy Society Professional society that provides information, support, and grants to physicians and health-care workers in the field of epilepsy 342 N. Main St. West Hartford, CT 06117 860-586-7505 http://www.aesnet.org
National Institute of Neurological Disorders and Strokes Provides research funding for neurological disorders, including epilepsy 9000 Rockville Pike Bethesda, MD 20892 www.ninds.nih.gov
Society for Neuroscience Professional society that provides information and support to neuroscientists 11 Dupont Circle Washington, DC 20036 202-462-6688 www.sfn.org
OTHER RESOURCES
Ketogenic Diet Resources on the Web www.mynchen.demon.co.uk/Ketogenic_diet/Resources/Ketogenic_diet_resources.htm
Stanford University Ketogenic Diet Web Site A web site packed with useful infonnation about KD formulation, resources, and frequently asked questions. www.stanford.edu/group/ketodiet/
E-mail list for parents of people on the ketogenic diet An e-maillistserve for families who have had experience with the ketogenic diet to share ideas, recipes, and moral support. To subscribe to this e-mail list, change the URL of your browser to http://www.squish.com/rickloeklketopages/.
Parents Helping Parents 3041 Olcott St. Santa Clara, CA 95054 1-408-727-5775 BBS 1-408-727-7227
Appendix B
SHS North America SHS is a world leader in specialized clinical nutrition. The company produces a ready-made ketogenic diet formula called KetoCal. 9900 Belward Campus Dr., Ste. 100 Rockville, MD 20850 800-365-7354 www.shsna.com
Ketocalculator
347
Ketocalculator is a web-based computer program for calculating the ketogenic diet prescription, ketogenic meals, and snacks. Recipes are included with special meals. An annual user fee is required, and the use of the Ketocalculator is restricted to dietitians.
Index
A
Absence seizures, 182 Acetazolamide, 58, 108 Acetoacetate (AcAc), 43, 129, 138, 180, 181,
188,206,209,217-226,249,295 Acetone, 104, 129-132, 138, 150,217-226 N-acetyl-aspartate (NAA), 144, 150 Acetyl-CoA, 179-181, 189 Action potentials, 14, 19, 136, 230 Adenosine, 21, 170 Adenosine triphosphate (ATP), 144, 149, 182,
239,258,267,294 Adrenocorticotrophic hormone (ACTH), 25, 27, 303 Adrenoreceptors, 269-271 Afterhyperpolarization (AHP), 14 Amino acids, 185-196, 209 Amygdala, 266-267, 281, 283, 290 Antidepressants, 268, 271 Antiepileptic drugs (AEDs) (see also specific
drugs), 25-27, 229 Arachidonic acid (AA), 133 Arcuate nucleus of hypothalamus, 280 Astrocytes, 185, 186, 191,202,208-212 Atkins' diet, 107, 154 Audiogenic seizures, 236
8
Barbiturates, 117, 231 Benzodiazepines, 25, 231 Bible, 31, 248 Bicuculline, 136, 233-234, 267 Bipolar disorder (manic-depressive disorder),
154, 156 Bleeding abnormalities, 125 Brain-derived neurotrophic factor (BDNF), 15
c Cable properties, 14 Calcium channels (see Channels, calcium), Calorie restriction, 161, 168-170,209, 229, 233,
237,240,247-259,271,309 Cancer, 154 Carbamazepine, 25, 136, 154, 231, 258, 270 Cardiovascular disease, 107, 125-126, 154, 155,
294
349
Camitine, 59, 123-124, 179 Camitine acyltransferase I, 179 Caspase-3, 292 c-fos, 266-267 Channels, ionic, 6, 12
calcium, 12, 25, 231, 233-234, 238, 294 chloride, 23 potassium, 136, 238-239
2P-domain, 165 calcium-dependent, 14 K-ATP, 238-239
sodium, 12,230,238,294-295 Charlie Foundation, 41 Cholesterol, 105-106, 155 Choline, 162-164 Ciprofibrate, 208 Clonidine, 269-270 Cobb, Stanley, 35-37 Conklin, Hugh W., 31-39, 96 Corpus callosum, 5 Corticotrophin releasing hormone, 15, 27 Cyclic AMP response element (CRE), 207
D
Dentate gyrus, 21, 170,296-297 2-Deoxyglucose (2-DG), 267 Diabetes, 155, 156 Dibenzylamine, 224 Diuretics, 118 Docosahaxaenoic acid (DHA), 133, 164-167 Dopamine-p-hydroxylase knockout mouse, 270-
273 Dysgenesis, cerebral, 112, 115
E
Eicosapentaenoic acid (EPA), 133 EL (epileptic) mouse, 249-259, 268, 293 Electroconvulsive therapy (ECT), 154 Electroencephalogram (EEG), 5, 7, 17, 95, 100-
101, 183 Electroshock, 224-225, 229-237, 266 (see also
Epilepsy models) Electrotonic synapses, 13-14 Energy metabolism, cerebral, 15-16, 179-183,
185-186
350
Energy reserve, 182 Epileptogenesis, 4, 16, 21, 255, 289-297 Epilepsy (see also Seizures)
classification, 4-6 consequences, 24 evaluation, 7-8 immature brain, 23 mechanisms, 3-27 models
acute, 221, 229-240 chronic, 249-255, 289-297
refractory, 8, 54, 99-100, 103, 111, 309 surgery, 8 syndromes, 4, 99, 112, temporal lobe, 21, 111, 144, 291, 296
Ethosuximide, 25, 231, 233 Excitatory postsynaptic potentials (EPSPs), 12-
13, 19, 295 Excitotoxicity, 165, 296
F
Fasting,38,57, 105,147,168,218,248,254,293 Fatty acids (see also Polyunsaturated fatty acids),
202, 204, 210, 218 Food and Drug Administration (FDA), 117, 305 Felbamate, 25, 303, 305 Flurothyl, 235, 266
G
Gabapentin, 154 Galanin, 267, 279-284 Galnon, 282 y-aminobutyric acid (GABA), 10, 21, 23, 104,
145, 150, 165, 192, 194, 196,211,230-236,239,258,265,281,293,295-297
depolarizing action, 23-24 GABA-A receptors, 10 GABA-B receptors, 10
y-butyrolactone (GBL), 233-4 y-hydroxybutyrate, 233-234, 249, 253-254 y-vinyl-GABA (GVG), 230, 237 Gene-environment interactions 250 Generalized tonic-clonic seizures, 182, 274, 304 Genetically epilepsy-prone rat (GEPR), 268 Geyelin, H. R., 33-41, 96 Glia (see also astrocytes), 185-195, 231, 256-258 Glucagon, 204,207 Glucocorticoids, 204, 206 Glucose, blood, 256-258
deprivation, 16 Glucose flux, 181 Glucose transporter type I (GLUT-I) deficiency,
113-115, 153, 156, 183, 256
Index
Glutamate, 136, 145, 150, 185-188, 191-192, 194,211,265,296
Glutamate oxaloacetate transaminase (GOT), 211 Glutamate transporter, 15 Glutamic acid decarboxylase, 258 Glutamine-glutamate cycle, 186-187, 210 Glycogen, 181, 182 Glycolysis, 145, 179, 181, 185, 189,256,258-9 G proteins, 10, 279 Growth rates, 124, 232
H
Hexokinase, 181 Hippocampus, 21, 136, 144, 164-165, 235, 249,
266,272-274,281,283-284,291,294-295
Hippocrates, 31 Howland, John, 36-37 ~-Hydroxybutyrate, 43, 104, 129, 138, 146-147,
180,181,188,202,206,209,217-226, 232,239,240,265,289,293,295
6-Hydroxydopamine (6-0HDA), 267, 284 ~-Hydroxylase knockout mouse, 267 3-Hydroxy-3-methyl-glutaryl-CoA synthase
(HMGCS2), 203-211, 233 Hyperbaric oxygen, 236 Hyperlipidemia, 88-89, 138 Hypersynchrony, neuronal, 16 Hypoglycorrhachia, 114, 153
I
Immediate early genes (lEG), 16, 266-267 Inborn errors of metabolism, 113 Infantile spasms, 25, 98, 112, 274 Infections, 125 Inhibitory postsynaptic potentials (IPSPs), 10, 13,
19 Insulin, 204, 206, 280-281, 283 Ischemia, 16 Isopropanolol, 223
K
Kainic acid (KA), 163, 169, 231, 233-235, 238, 266-267,282,284,291-292,296
KCC2, 23 2-Ketoglutarate, 185 Ketogenic diet
adults, 42, 103-108 age, 100, 112 bleeding abnormalities, 125 calculation
carbohydrate, 67, 69 cream, 69
Index
dietary units, 66 energy requirements, 65 fat, 67,69 fluid, 73 ketogenic ratio, 66 meal, 69 protein, 67, 69 vitamins and minerals, 73
cardiac complications, 126 cognitive effects, 95 compliance, 54, 64 complications, 64, 75-77, 107-108, 123-127 composition, 68 contraindications, 55 cost effectiveness, 90 dietician's role, 58, 86-87, 105 discontinuation, 59-60, 78-79 efficacy, 42, 44-46, 95-101, 103, 106, 113 growth effects, 124-125 history, 31-47,96 infants, 98, 123 infections, 125 initiation, 57-58, 74-75 laboratory studies, baseline, 55, 64, 84, 105 medical follow-up, 58, 77-78 monitoring nurse's role, 83-93 optic neuropathy, 126 outpatient initiation, 88 pancreatitis, 126 patient selection, 53-54, 63-64, 84 pharmacist's role, 88 resources, 90, screening laboratory studies, 55, 64, 84, 105 support groups, 89 surgery, 89, 92-93 timeline, 56
Ketogenic ratio, 66 Ketogenesis, 179, 185,202,204,206,209,212 Ketone bodies (see acetoacetate, acetone,
13-hydroxybutyrate) Ketones, urinary, 43, 58, 130, 221 Ketosis, 129-139, 143-150 Kidney stones, 58, 64, 108, 124 Kindling, 225, 266, 282, 290, 296-297 (see also
Epilepsy models) Kwashiorkor, 252
L
Lactate, 16, 115, 185, 256-257 Lamotrigine, 25, 154, 270 Lennox-Gastaut syndrome, 54, 112, 148, 182,
303-304
Leptin, 280-281, 283 Leucine, 209 Linoleic acid (LA), 133 a-Linolenic acid (ALA), 133 Lipoproteins, 155 Lithium, 154 Locus coeruleus, 266-273, 284
M
Magnetic resonance imaging, 7, 22
351
Magnetic resonance spectroscopy, 132, 143-150, 182,219,222
Malonyl-CoA, 179 MacFadden, Bemarr, 31-35 Malnutrition, 169-170 Medium chain triglycerides (MCTs), 40, 42-43,
97,132,219,231-232 a-Melanocyte-stimulating hormone (a-MSH),
280 Mitochondria, 116,123,179,180,189,202,206,
256-258,293-295 Monocarboxylate transporter, 132, 188, 258 Mossy fiber sprouting, 21-22, 250, 291-292, 296 Myoclonic seizures, 274
N
N-methyl-o-aspartate (NMDA) receptors, 12, 19, 25, 164, 136, 164, 194, 233, 235
NAD/NADH, 181, 188-189, 202 Neuropeptide Y (NPY), 15, 267, 279-284 Neuroprotection, 169, 290, 295 Non-N-methyl-o-aspartate (non-NMDA) recep-
tors, 25 Norepinephrine, 265-274, 279
0
Obesity, 154, 156 Open field test, 240 Optic neuropathy, 126 Oxaloacetate, 185 Oxidation (j3, fatty acid), 55, 116-117, 123, 137,
202-204,207,209,212,281,283 Oxygen consumption, cerebral, 185
p
Paired-pulse inhibition, 297 Palmitate, 203, 209 Pancreatitis, 126 Paroxysmal depolarization shift (PDS), 19 Partial complex seizures, 182, 274 Pentylenetetrazole (PTZ), 136, 166-167, 208,
224,225,231-237,239,266,282,284(see also Epilepsy models)
352
Perforant path stimulation, 284, 296 Peroxisome proliferator-activated receptor-a
protein (PPARa), 204-213 Peterman, M.G., 38-39, 96 Phenobarbital, 25, 258, 270, 296 Phenytoin,25,96, 136,213,223,229,230-231,
239,258,270 Phosphocreatine (PCr), 144 Phosphorylation, 239 Picrotoxin, 230, 233-234, 266, 282 Pilocarpine, 231, 267, 296 (see also Epilepsy
models) Platelets, 138 Polyunsaturated fatty acids (PUFA), 133, 136-
138,161,164-168,293-294 Porphyrias, 117, 123 Positron emission tomography (PET), 8, 16, 143,
146, 183 Prepromelanocortin (POMC) neurons, 280 Pyruvate, 256-257 Pyruvate carboxylase deficiency, 55 Pyruvate dehydrogenase deficiency, 115-116
Q
Quaking mouse, 268 QT interval, 108, 125-126, 155
R
Raphael, 31-32 Reactive oxygen species (ROS), 294-295 Retigabine, 237 Rett syndrome, 113 Rheumatoid arthritis, 156 Rolandic epilepsy, benign, 5 Rotorod, 230
s Second messengers, 6 Seizures (see also Epilepsy)
mechanisms, 3-27 propagation, 20 termination, 21 types, 99, 103, 111
Serotonin selective reuptake inhibitors (SSRis), 268
Single-photon-emission computed tomography (SPECT), 8
Sodium-potassium ATPase, 14-15 Soman, 267 Somatostatin, 15 Spectroscopy, 143-150 Spreading depression, 297 Sprouting, 21, 22, 296
Index
Starvation, 169-170, 181, 204, 217, 222, 240, 252
Status epilepticus, 16, 22, 162, 231, 234-235, 238,267,291-292,296
Steroids, 118 Strychnine, 234 Substantia nigra, 165,231,296 Succinyl-CoA, 181 Synaptic function, 8-14
T
Tiagabine, 25 Timm histochemistry, 291 Topiramate, 58, 108, 118 Tottering mouse, 268 Transcription factors, 204, 205 Tricarboxylic acid cycle (TCA; Kreb's cycle),
145, 179, 181, 185-186,206,256,258 TUNEL staining, 292 Tyrosine hydroxylase (TH), 267-268
u Uncoupling proteins (UCPs), 294-295
v Vagus nerve stimulation (VNS), 8, 53, 111, 154,
258-259,270-271 Valproate, 136, 154, 166,213,231,239,258
toxicity, 126 Vigabatrin (see also y-vinyl-GABA), 25, 258, 296 Vitamins, 73, 161
w Water maze, 163, 240 Wilder, R. M., 38, 96
z
Zonisamide, 58, 108, 118
About the Editors
Carl E. Stafstrom, MD, PhD is Professor of Neurology and Pediatrics and Chief of the Division of Pediatric Neurology at the University of Wisconsin Medical School, Madison, WI. He received his AB from the University of Pennsylvania, followed by MD and PhD degrees (the latter in physiology and biophysics) from the University of Washington, Seattle. After completing a residency in pediatrics at the University of Washington Children's Hospital, Dr. Stafstrom trained in adult and pediatric neurology at TuftsNew England Medical Center in Boston, followed by fellowships in neurology research, epilepsy, and clinical neurophysiology at Children's Hospital, Harvard Medical School, Boston. Prior to his current position, he held faculty appointments at Duke University Medical Center and Tufts University School of Medicine.
Dr. Stafstrom's main research interests are the pathophysiological mechanisms of epilepsy in the developing brain, the consequences of
seizures on cognition and behavior, and alternative epilepsy therapies such as the ketogenic diet. He actively pursues these interests in both the clinic and the laboratory.
Dr. Stafstrom is author of more than 100 publications on epilepsy and its mechanisms. He serves as chair of the scientific review committee of Partnership for Epilepsy Research and on the scientific advisory boards of the Epilepsy Foundation and the Charlie Foundation. He is the former chair of the Investigators Workshop Committee of the American Epilepsy Society. Dr. Stafstrom serves on the editorial boards of the journals Epilepsia and Epilepsy Currents. He is the recipient of numerous awards for teaching and research.
Jong M. Rho, MD is Associate Director of Child Neurology and Director of Pediatric Epilepsy Research at the Barrow Neurological Institute and St. Joseph's Hospital and Medical Center in Phoenix, Arizona. He received his BA at Yale University with a major in molecular biophysics and biochemistry, and completed his MD at the University of Cincinnati College of Medicine. He obtained residency training in pediatrics at the Los Angeles Children's Hospital, affiliated with the University of Southern California School of Medicine, and completed a neurology residency at the University of California Los Angeles School of Medicine. Dr. Rho then pursued a basic science fellowship in neuropharmacology in the Epilepsy Research Branch at the National Institute of Neurological Disorders and Stroke in Bethesda, Maryland. Prior to his current position, he was the director of the pediatric epilepsy program at the University of Washington School of Medicine and Seattle Children's Hospital and Regional Medical Center, as well as the director of the University of California at Irvine Comprehensive Epilepsy Program for adults and children, where he was also an Associate Professor of pediatrics and neurology.
Dr. Rho's main research interests have been in anticonvulsant drug mechanisms, developmental animal models of epilepsy, and the basic mechanisms underlying the anticonvulsant and potentially neuroprotective actions of the ketogenic diet. His research has been funded for the past 8 years by the NIH, Epilepsy Foundation of America, and the Charlie Foundation. He has authored or co-authored more than 45 clinical and scientific publications, and has co-edited two additional books on the subject of epilepsy.
Dr. Rho is a recipient of several teaching awards, has been actively involved in resident and fellow education throughout the years, and has organized numerous clinical and scientific symposia and meetings at both national and international levels. He has served as an ad hoc reviewer on two NIH study sections, and is on the scientific advisory board of the Charlie Foundation.
About the Series Editor
Dr. Adrianne Bendich is Clinical Director of Calcium Research at GlaxoSmithKline Consumer Healthcare, where she is responsible for leading the innovation and medical programs in support of TUMS and Os-Cal. Dr. Bendich has primary responsibility for the direction ofGSK's support for the Women's Health Initiative intervention study. Prior to joining GlaxoSmithKline, Dr. Bendich was at Roche Vitamins Inc., and was involved with the groundbreaking clinical studies proving that folic acid-containing multivitamins significantly reduce major classes of birth defects. Dr. Bendich has co-authored more than 100 major clinical research studies in the area of preventive nutrition. Dr. Bendich is recognized as a leading authority on antioxidants, nutrition, immunity, and pregnancy outcomes, vitamin safety, and the cost-effectiveness of vitamin/mineral supplementation.
In addition to serving as Series Editor for Humana Press and initiating the development of the 15 currently published books in the Nutrition and Health™ series, Dr. Bendich is the editor of nine books, including Preventive Nutrition: The Comprehensive Guide for Health Professionals. She also serves as Associate Editor for Nutrition: The International Journal of Applied and Basic Nutritional Sciences, and Dr. Bendich is on the Editorial Board of the Journal of Women's Health and Gender-Based Medicine, as well as a past member of the Board of Directors of the American College of Nutrition.
Dr. Bendich was the recipient of the Roche Research Award, a Tribute to Women and Industry Awardee, and a recipient of the Burroughs Wellcome Visiting Professorship in Basic Medical Sciences, 2000-200 l . Dr. Bendich holds academic appointments as Adjunct Professor in the Department of Preventive Medicine and Community Health at UMDNJ, Institute of Nutrition, Columbia University P&S, and Adjunct Research Professor, Rutgers University, Newark Campus. She is listed in Who's Who in American Women.
